MXPA00002245A - Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds - Google Patents
Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compoundsInfo
- Publication number
- MXPA00002245A MXPA00002245A MXPA/A/2000/002245A MXPA00002245A MXPA00002245A MX PA00002245 A MXPA00002245 A MX PA00002245A MX PA00002245 A MXPA00002245 A MX PA00002245A MX PA00002245 A MXPA00002245 A MX PA00002245A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- amino
- propionylamino
- dihydro
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 210000000988 Bone and Bones Anatomy 0.000 title claims description 13
- 229940079593 drugs Drugs 0.000 title claims description 6
- 208000008466 Metabolic Disease Diseases 0.000 title claims description 4
- 239000004475 Arginine Substances 0.000 title claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 title description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 125000005842 heteroatoms Chemical group 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 238000006467 substitution reaction Methods 0.000 claims abstract description 8
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims abstract description 7
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 6
- 239000000651 prodrug Substances 0.000 claims abstract description 6
- 229940002612 prodrugs Drugs 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 125000002619 bicyclic group Chemical group 0.000 claims abstract description 5
- 230000003287 optical Effects 0.000 claims abstract description 4
- 125000001151 peptidyl group Chemical group 0.000 claims abstract description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 claims description 10
- 150000004703 alkoxides Chemical class 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 208000003432 Bone Disease Diseases 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 230000002194 synthesizing Effects 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000004679 hydroxides Chemical group 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 abstract description 187
- 235000001014 amino acid Nutrition 0.000 abstract description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 168
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 229910052757 nitrogen Inorganic materials 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000969 carrier Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 101700067048 CDC13 Proteins 0.000 description 9
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000012159 carrier gas Substances 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001307 helium Substances 0.000 description 6
- 229910052734 helium Inorganic materials 0.000 description 6
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 229960000583 Acetic Acid Drugs 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 238000006065 biodegradation reaction Methods 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-Ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 230000035693 Fab Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N Norvaline Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 229960003692 aminobutyric acid Drugs 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000004896 high resolution mass spectrometry Methods 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 108010005195 parathyroid hormone-related protein (107-111) Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HNPOSBLBOOYMLT-UHFFFAOYSA-N tert-butyl 3-(acetyloxymethyl)-2,5-dihydropyrrole-1-carboxylate Chemical compound CC(=O)OCC1=CCN(C(=O)OC(C)(C)C)C1 HNPOSBLBOOYMLT-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 210000002997 Osteoclasts Anatomy 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atoms Chemical group C* 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000008079 hexane Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000000790 osteoblast Effects 0.000 description 3
- 230000002148 osteoclast Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N α-Aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2S)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- XRUAYOALCCFEAE-UHFFFAOYSA-N 2,5-dihydropyrrole-1,3-dicarboxylic acid Chemical compound OC(=O)N1CC=C(C(O)=O)C1 XRUAYOALCCFEAE-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- CWAYDJFPMMUKOI-UHFFFAOYSA-N 2-amino-2-methylbutanedioic acid Chemical compound OC(=O)C(N)(C)CC(O)=O CWAYDJFPMMUKOI-UHFFFAOYSA-N 0.000 description 2
- ASBJGPTTYPEMLP-UHFFFAOYSA-N 2-azaniumyl-3-chloropropanoate Chemical compound ClCC(N)C(O)=O ASBJGPTTYPEMLP-UHFFFAOYSA-N 0.000 description 2
- LDRFQSZFVGJGGP-UHFFFAOYSA-N 2-azaniumyl-3-hydroxy-3-methylbutanoate Chemical compound CC(C)(O)C(N)C(O)=O LDRFQSZFVGJGGP-UHFFFAOYSA-N 0.000 description 2
- ZAYJDMWJYCTABM-UHFFFAOYSA-N 2-azaniumyl-3-hydroxy-4-methylpentanoate Chemical compound CC(C)C(O)C(N)C(O)=O ZAYJDMWJYCTABM-UHFFFAOYSA-N 0.000 description 2
- CDUUKBXTEOFITR-UHFFFAOYSA-N 2-methylserine zwitterion Chemical compound OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N Bis(trimethylsilyl)amine Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 210000002805 Bone Matrix Anatomy 0.000 description 2
- 102100000129 CHURC1 Human genes 0.000 description 2
- 101710014631 CHURC1 Proteins 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical group 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M Methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
- 229940012189 Methyl orange Drugs 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 101710027499 Os03g0268000 Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M Sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RQVLGLPAZTUBKX-VKHMYHEASA-N Vinylglycine Chemical compound C=C[C@H](N)C(O)=O RQVLGLPAZTUBKX-VKHMYHEASA-N 0.000 description 2
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- WZCZNEGTXVXAAS-UHFFFAOYSA-N trifluoromethanol Chemical compound OC(F)(F)F WZCZNEGTXVXAAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- UTNFXXOYUNRYBI-SCSAIBSYSA-N (2R)-2-amino-2-cyanopropanoic acid Chemical compound N#C[C@](N)(C)C(O)=O UTNFXXOYUNRYBI-SCSAIBSYSA-N 0.000 description 1
- HUPVCGRDUVJYEN-AKGZTFGVSA-N (2R)-2-amino-3-fluorohexanoic acid Chemical compound CCCC(F)[C@H](N)C(O)=O HUPVCGRDUVJYEN-AKGZTFGVSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-azaniumylcyclobutane-1-carboxylate Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PECYZEOJVXMISF-REOHCLBHSA-N 2,3-Diaminopropionic acid Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 1
- PGNYNCTUBKSHHL-UHFFFAOYSA-N 2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)C(N)C(O)=O PGNYNCTUBKSHHL-UHFFFAOYSA-N 0.000 description 1
- LJWBJESKXYIROZ-UHFFFAOYSA-N 2-[2-[2-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]propanoylamino]propanoylamino]-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 LJWBJESKXYIROZ-UHFFFAOYSA-N 0.000 description 1
- WHAAHDMMPVRDRX-UHFFFAOYSA-N 2-[3-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]propanoylamino]-2-thiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(C(O)=O)NC(=O)CCNC(=O)C(N)CC1=CCN(C(N)=N)C1 WHAAHDMMPVRDRX-UHFFFAOYSA-N 0.000 description 1
- LELKQHJDFAGLOL-UHFFFAOYSA-N 2-[3-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]propanoylamino]-3-(3,5-dimethyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=CC=C(C)C=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCNC(=O)C(N)CC1=CCN(C(N)=N)C1 LELKQHJDFAGLOL-UHFFFAOYSA-N 0.000 description 1
- OSJIORMLDHMGMJ-UHFFFAOYSA-N 2-[4-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(5-ethyl-3-methyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound CC=1C2=CC(CC)=CC=C2OC=1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(NC(=O)C(N)C(C)O)CC1=CCN(C(N)=N)C1 OSJIORMLDHMGMJ-UHFFFAOYSA-N 0.000 description 1
- FACWQKDXQINZJX-UHFFFAOYSA-N 2-[4-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(7-ethyl-3-methyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C=2C(CC)=CC=CC=2C(C)=C1CC(C(O)=O)NC(=O)CCCNC(=O)C(NC(=O)C(N)C(C)O)CC1=CCN(C(N)=N)C1 FACWQKDXQINZJX-UHFFFAOYSA-N 0.000 description 1
- DAJJHJQDLWRLRP-UHFFFAOYSA-N 2-[4-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-hydroxy-3-(5-methylthiophen-2-yl)propanoic acid Chemical compound C=1C=C(C)SC=1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 DAJJHJQDLWRLRP-UHFFFAOYSA-N 0.000 description 1
- IUSZBPHBCQUEDS-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-2-cyclohexylacetic acid Chemical compound C1CCCCC1C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 IUSZBPHBCQUEDS-UHFFFAOYSA-N 0.000 description 1
- YKZDYKVFOAOPFJ-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(1-benzothiophen-2-yl)propanoic acid Chemical compound C=1C2=CC=CC=C2SC=1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 YKZDYKVFOAOPFJ-UHFFFAOYSA-N 0.000 description 1
- WHURHJWUMFKYBJ-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(3,4-dimethyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=CC=CC(C)=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 WHURHJWUMFKYBJ-UHFFFAOYSA-N 0.000 description 1
- FLUXJLAWUAEYGL-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(3,6-dimethyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=CC(C)=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 FLUXJLAWUAEYGL-UHFFFAOYSA-N 0.000 description 1
- YXZSSHZQOCDFOK-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(3,7-dimethyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=C(C)C=CC=C2C(C)=C1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 YXZSSHZQOCDFOK-UHFFFAOYSA-N 0.000 description 1
- NQCGUMJAILYINS-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(3-methyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=CC=CC=C2C(C)=C1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 NQCGUMJAILYINS-UHFFFAOYSA-N 0.000 description 1
- TXIYBSISENRPTE-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(5-ethyl-3-methyl-1-benzofuran-2-yl)propanoic acid Chemical compound CC=1C2=CC(CC)=CC=C2OC=1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 TXIYBSISENRPTE-UHFFFAOYSA-N 0.000 description 1
- ADSDAKDWINQDPO-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(5-ethylthiophen-2-yl)propanoic acid Chemical compound S1C(CC)=CC=C1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 ADSDAKDWINQDPO-UHFFFAOYSA-N 0.000 description 1
- WUCCMNFLLIDECQ-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(5-methylthiophen-2-yl)propanoic acid Chemical compound S1C(C)=CC=C1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 WUCCMNFLLIDECQ-UHFFFAOYSA-N 0.000 description 1
- IXPXBCCIOICXKM-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(6-hydroxy-1H-indol-2-yl)propanoic acid Chemical compound C=1C2=CC=C(O)C=C2NC=1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 IXPXBCCIOICXKM-UHFFFAOYSA-N 0.000 description 1
- IJJDDVKVBRVSAA-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(7-chloro-3-methyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=C(Cl)C=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 IJJDDVKVBRVSAA-UHFFFAOYSA-N 0.000 description 1
- GBBRMFSFHDUDPU-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(7-ethyl-3-methyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C=2C(CC)=CC=CC=2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 GBBRMFSFHDUDPU-UHFFFAOYSA-N 0.000 description 1
- GXLIHRJKAAQQPZ-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-(furan-2-yl)-3-hydroxypropanoic acid Chemical compound C=1C=COC=1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 GXLIHRJKAAQQPZ-UHFFFAOYSA-N 0.000 description 1
- YISDXQMVMFSDST-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-[5-(hydroxymethyl)furan-2-yl]propanoic acid Chemical compound C=1C=C(CO)OC=1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 YISDXQMVMFSDST-UHFFFAOYSA-N 0.000 description 1
- BNQIZRMYQLBRHL-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-hydroxy-3-pyridin-4-ylpropanoic acid Chemical compound C=1C=NC=CC=1C(O)C(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 BNQIZRMYQLBRHL-UHFFFAOYSA-N 0.000 description 1
- UJBWRJBQUTTWSE-UHFFFAOYSA-N 2-[4-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]butanoylamino]-3-thiophen-2-ylpropanoic acid Chemical compound C=1C=CSC=1CC(C(O)=O)NC(=O)CCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 UJBWRJBQUTTWSE-UHFFFAOYSA-N 0.000 description 1
- KKKXLVAPIZVFAF-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(3,5-dimethyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=CC=C(C)C=C2C(C)=C1CC(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 KKKXLVAPIZVFAF-UHFFFAOYSA-N 0.000 description 1
- QUZLBPMMMAQMNK-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(3,6-dimethyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=CC(C)=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 QUZLBPMMMAQMNK-UHFFFAOYSA-N 0.000 description 1
- NTIZZMVLBXAZSM-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(5-ethylthiophen-2-yl)propanoic acid Chemical compound S1C(CC)=CC=C1CC(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(C)O)CC1=CCN(C(N)=N)C1 NTIZZMVLBXAZSM-UHFFFAOYSA-N 0.000 description 1
- LKDMYZSCOKZVKN-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(5-methylthiophen-2-yl)propanoic acid Chemical compound C=1C=C(C)SC=1CC(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 LKDMYZSCOKZVKN-UHFFFAOYSA-N 0.000 description 1
- PEROKVWXQSTZBQ-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(7-chloro-3-methyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=C(Cl)C=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 PEROKVWXQSTZBQ-UHFFFAOYSA-N 0.000 description 1
- TUFXBDRYWVYULM-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-hydroxy-3-pyridin-4-ylpropanoic acid Chemical compound C=1C=NC=CC=1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 TUFXBDRYWVYULM-UHFFFAOYSA-N 0.000 description 1
- XWVIRNHDJWQWJQ-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-hydroxy-3-thiophen-2-ylpropanoic acid Chemical compound C=1C=CSC=1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 XWVIRNHDJWQWJQ-UHFFFAOYSA-N 0.000 description 1
- YFWRLDSLSPJDAT-UHFFFAOYSA-N 2-[5-[[2-[(2-amino-3-hydroxybutanoyl)amino]-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-thiophen-2-ylpropanoic acid Chemical compound C=1C=CSC=1CC(C(O)=O)NC(=O)CCCCNC(=O)C(NC(=O)C(N)C(O)C)CC1=CCN(C(N)=N)C1 YFWRLDSLSPJDAT-UHFFFAOYSA-N 0.000 description 1
- GPJKSSYJCNTBKZ-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(3,4-dimethyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=CC=CC(C)=C2C(C)=C1CC(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 GPJKSSYJCNTBKZ-UHFFFAOYSA-N 0.000 description 1
- DPLFVETYVUDVNI-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(3,6-dimethyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=CC(C)=CC=C2C(C)=C1CC(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 DPLFVETYVUDVNI-UHFFFAOYSA-N 0.000 description 1
- WUIMUUUVMDHKMK-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(3,7-dimethyl-1-benzofuran-2-yl)-3-hydroxypropanoic acid Chemical compound O1C2=C(C)C=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 WUIMUUUVMDHKMK-UHFFFAOYSA-N 0.000 description 1
- IBCJNQPWBLABQM-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(7-ethyl-3-methyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C=2C(CC)=CC=CC=2C(C)=C1CC(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 IBCJNQPWBLABQM-UHFFFAOYSA-N 0.000 description 1
- NNPLKUSJOFKGSF-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-(cyclopenten-1-yl)propanoic acid Chemical compound C=1CCCC=1CC(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 NNPLKUSJOFKGSF-UHFFFAOYSA-N 0.000 description 1
- ONFLTICMHRWXEP-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-hydroxy-3-(3-methyl-1-benzofuran-2-yl)propanoic acid Chemical compound O1C2=CC=CC=C2C(C)=C1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 ONFLTICMHRWXEP-UHFFFAOYSA-N 0.000 description 1
- NEXZDHKIFRKSAK-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-hydroxy-3-(5-methylthiophen-2-yl)propanoic acid Chemical compound S1C(C)=CC=C1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 NEXZDHKIFRKSAK-UHFFFAOYSA-N 0.000 description 1
- WCANSKWEZBRUKL-UHFFFAOYSA-N 2-[5-[[2-amino-3-(1-carbamimidoyl-2,5-dihydropyrrol-3-yl)propanoyl]amino]pentanoylamino]-3-hydroxy-3-pyridin-3-ylpropanoic acid Chemical compound C=1C=CN=CC=1C(O)C(C(O)=O)NC(=O)CCCCNC(=O)C(N)CC1=CCN(C(N)=N)C1 WCANSKWEZBRUKL-UHFFFAOYSA-N 0.000 description 1
- PWDYHRMBGRYCAP-UHFFFAOYSA-N 2-amino-3-methylsulfanylbutanoic acid Chemical compound CSC(C)C(N)C(O)=O PWDYHRMBGRYCAP-UHFFFAOYSA-N 0.000 description 1
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 1
- DYFYPSCJKBYYNK-UHFFFAOYSA-N 2-azaniumyl-2-(furan-2-yl)acetate Chemical compound OC(=O)C(N)C1=CC=CO1 DYFYPSCJKBYYNK-UHFFFAOYSA-N 0.000 description 1
- VRFYYCFVOBCXDL-UHFFFAOYSA-N 2-azaniumyl-2-cyclopropylpropanoate Chemical compound OC(=O)C(N)(C)C1CC1 VRFYYCFVOBCXDL-UHFFFAOYSA-N 0.000 description 1
- QMBTZYHBJFPEJB-UHFFFAOYSA-N 2-azaniumyl-2-methylpent-4-enoate Chemical compound OC(=O)C(N)(C)CC=C QMBTZYHBJFPEJB-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 2-azaniumyl-3-cyanopropanoate Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- ZFUKCHCGMBNYHH-UHFFFAOYSA-N 2-azaniumyl-3-fluoro-3-methylbutanoate Chemical compound CC(C)(F)C(N)C(O)=O ZFUKCHCGMBNYHH-UHFFFAOYSA-N 0.000 description 1
- HJVQOHDATXHIJL-UHFFFAOYSA-N 2-azaniumyl-3-fluorobutanoate Chemical compound CC(F)C(N)C(O)=O HJVQOHDATXHIJL-UHFFFAOYSA-N 0.000 description 1
- RDBBJCUJCNMAAF-UHFFFAOYSA-N 2-azaniumyl-3-methoxy-3-methylbutanoate Chemical compound COC(C)(C)C(N)C(O)=O RDBBJCUJCNMAAF-UHFFFAOYSA-N 0.000 description 1
- FYCWLJLGIAUCCL-UHFFFAOYSA-N 2-azaniumyl-3-methoxybutanoate Chemical compound COC(C)C(N)C(O)=O FYCWLJLGIAUCCL-UHFFFAOYSA-N 0.000 description 1
- KNTFCRCCPLEUQZ-UHFFFAOYSA-N 2-azaniumyl-3-methoxypropanoate Chemical compound COCC(N)C(O)=O KNTFCRCCPLEUQZ-UHFFFAOYSA-N 0.000 description 1
- KTKWUKAYWFMQSO-UHFFFAOYSA-N 2-thiophen-2-ylpropanoic acid Chemical compound OC(=O)C(C)C1=CC=CS1 KTKWUKAYWFMQSO-UHFFFAOYSA-N 0.000 description 1
- ZZTHFRQFOGECDF-UHFFFAOYSA-N 3-(acetyloxymethyl)-2,5-dihydropyrrole-1-carboxylic acid Chemical compound CC(=O)OCC1=CCN(C(O)=O)C1 ZZTHFRQFOGECDF-UHFFFAOYSA-N 0.000 description 1
- AUICWCWKEKGFJO-UHFFFAOYSA-N 3-(hydroxymethyl)-2,5-dihydropyrrole-1-carboxylic acid Chemical compound OCC1=CCN(C(O)=O)C1 AUICWCWKEKGFJO-UHFFFAOYSA-N 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LGVJIYCMHMKTPB-UHFFFAOYSA-N 3-hydroxynorvaline Chemical compound CCC(O)C(N)C(O)=O LGVJIYCMHMKTPB-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VPGUFRIFJOZYAI-UHFFFAOYSA-N 4-benzoyloxypyrrolidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1CN(C(O)=O)CC1OC(=O)C1=CC=CC=C1 VPGUFRIFJOZYAI-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UAOQCNDSSZGMDA-UHFFFAOYSA-N 4-hydroxypyrrolidine-1,3-dicarboxylic acid Chemical compound OC1CN(C(O)=O)CC1C(O)=O UAOQCNDSSZGMDA-UHFFFAOYSA-N 0.000 description 1
- XZIWQZAWDDJDKR-UHFFFAOYSA-N 4-oxopyrrolidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1CN(C(O)=O)CC1=O XZIWQZAWDDJDKR-UHFFFAOYSA-N 0.000 description 1
- OLUWXTFAPJJWPL-YFKPBYRVSA-N 6-Hydroxy-L-Norleucine Chemical compound OC(=O)[C@@H](N)CCCCO OLUWXTFAPJJWPL-YFKPBYRVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- QLTCYXXUAPJHDM-UHFFFAOYSA-N C(C)C1=CC=CC=2C(=C(OC=21)C(C(=O)O)CO)C Chemical compound C(C)C1=CC=CC=2C(=C(OC=21)C(C(=O)O)CO)C QLTCYXXUAPJHDM-UHFFFAOYSA-N 0.000 description 1
- RBTKMEUEBBMEEK-FMMPLYQGSA-O C[S+](C[C@@H](C(=O)O)N)SC[C@@H](C(=O)O)N Chemical compound C[S+](C[C@@H](C(=O)O)N)SC[C@@H](C(=O)O)N RBTKMEUEBBMEEK-FMMPLYQGSA-O 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N Cycloleucine Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N DL-alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- GCHPUFAZSONQIV-UHFFFAOYSA-N Isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L Magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N N'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- PWBJWDKDPAPGED-UHFFFAOYSA-N N'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 1
- KADXVMRYQRCLAH-UHFFFAOYSA-N N'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N N-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 229940043230 Sarcosine Drugs 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 102100014320 TGFB1 Human genes 0.000 description 1
- 101700041213 TGFB1 Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- APDDLLVYBXGBRF-UHFFFAOYSA-N [diethyl-(triethylsilylamino)silyl]ethane Chemical compound CC[Si](CC)(CC)N[Si](CC)(CC)CC APDDLLVYBXGBRF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-J aluminum;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-J 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940000635 beta-Alanine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000000473 carbonimidoyl group Chemical group [H]\N=C(/*)* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004721 gamma keto acids Chemical class 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ADPQWEGXWVSSKZ-UHFFFAOYSA-N pyrrolidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)C1 ADPQWEGXWVSSKZ-UHFFFAOYSA-N 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YSHDPXQDVKNPKA-UHFFFAOYSA-N tert-butyl 2-(benzhydrylideneamino)acetate Chemical compound C=1C=CC=CC=1C(=NCC(=O)OC(C)(C)C)C1=CC=CC=C1 YSHDPXQDVKNPKA-UHFFFAOYSA-N 0.000 description 1
- QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl N-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- OJQNRNQELNLWHH-UHFFFAOYSA-N α-Fluoro-β-alanine Chemical compound NCC(F)C(O)=O OJQNRNQELNLWHH-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N α-aminoisobutanoic acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- ZAYJDMWJYCTABM-WHFBIAKZSA-N β-Hydroxyleucine Chemical compound CC(C)[C@H](O)[C@H](N)C(O)=O ZAYJDMWJYCTABM-WHFBIAKZSA-N 0.000 description 1
Abstract
The present invention is directed to compounds of general formula (I), wherein R1, R2, R3 and X may be the same or different, and wherein R1, R2 represent hydrogen, an amino acid, peptidyl, alkyl or aryl residue;R3 represents hydroxy, lower alkoxy, or an -NR31R32 residue, where R31, R32 represent independently hydrogen, an aminoacid, peptidyl, alkyl or aryl residue;X represents an amino acid or a peptide;R4 represents hydrogen, hydroxy, amino or C1-C4 alkyl;m represents a number between 0 and 5;R5 represents an optionally substituted saturated or unsaturated mono- or bicyclic moiety which may contain one or more heteroatoms, a C1-C11 alkyl group which may have substitutions or intermittent heteroatoms, their tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs as well as their production and their use as medicaments.
Description
P eptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production and drugs containing these compounds.
The present invention relates to new peptide mimetics for the treatment of bone disorders, methods for their production and drugs containing these compounds.
In healthy individuals the processes of bone formation and degradation are virtually in balance, that is, the activity of osteoblasts and osteoclasts is balanced. However, if this balance is disturbed in favor of osteoclasts and / or disadvantaged by osteoblasts, a reduction in bone mass and a negative change in bone structure and function could result.
Until now, inhibitors of bone resorption such as estrogens, calcitonin and bisphosphates are primarily used in the treatment of bone metabolic disorders. However the use of these substances the limited and in addition, do not show the desired effects in all cases. Compounds that have a stimulating effect on bone formation and contribute to EEF .: 32843 increase an already diminished bone mass are therefore of particular importance in the treatment of bone disorders.
It is known that PTHrP (107-111) and the peptide derivatives thereof have a positive influence on the inhibition of bone resorption (WO 92/0511, WO 92/9424153). However, valin et al, in cell physiol. 170 (2), 209-15 (1997), describe an anti-proliferative effect of PTHrP (107-111) on UMR106 cells. Witfield et al. In J. Cell Physiol 166. { 1), 1-11 (1996) demonstrated a stimulating effect on PKC and a modulation of keratinocyte proliferation by PTHrP (107-111), whereas Kali et al. In Endocrinology 136 (3), 842-8 (1995) describes a stimulation of osteoclasts by PTHrP (107-111).
Surprisingly, it has now been found that the mimetic peptides of the present invention have a stimulating effect on bone formation and thus, are suitable for the general treatment of bone disorders. In particular, they can be used perfectly well in those cases where bone formation is disturbed, that is, they are particularly suitable for the treatment of osteopenic diseases of the skeletal system, such as osteoporosis, brittle bone disease, among others, such as for example , in orthopedic and orthodontic indications, in the healing of fractures, osteosynthesis, pseudodartrosis and for bone implants that become incorporated.
Due to these properties, they are also used in the prophylaxis of osteoporosis.
On the other hand, due to their influence on bone metabolism, the medicaments containing the mimetic peptide of the present invention as active substances constitute the basis for the local and systemic treatment of rheumatoid arthritis, osteoarthritis and degenerative osteoarthritis.
The present invention is directed to compounds of general formula (I)
Where
Ri, R2, R3 and X which can be the same or different and - where Ri, R2 represent hydrogen, an amino acid, peptidyl, alkyl or aryl radical; R3 represents hydroxide radical, lower alkoxide, or an -NR3? R32, wherein R31, R32 independently represent hydrogen, an amino acid, peptide, alkyl or aryl radical; X represents an amino acid or a peptide;
R 4 represents hydrogen, hydroxide, amino or a C 1 -C 4 -alkyl;
m represents a number between 0 and 5;
Rs represents an optionally saturated or unsaturated mono- or bicyclic portion or may contain one or more heteroatoms, an alkyl group of CL-CH which may contain intermittent substitutions or heteroatoms; its tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs.
X is preferably a D-amino acid or the dipeptide seryllalaryl;
R4 preferably represents methyl or hydroxide;
R1 and R2 are independently from each other preferably hydrogen;
R3 is preferably hydroxide or amine;
m is preferably 1 to 3, more preferably 1;
The residue (CHR4) mR5 represents especially a preferred radical linked to Ca of a proteinogenic or non-proteinogenic amino acid.
Alkaline salts, alkaline earth salts such as Ca or Mg salts, ammonium salts, acetates or hydrochlorides are generally used as pharmaceutically acceptable salts which are produced in the usual manner for example by triple treatment of the compounds with organic or inorganic bases or inorganic acids such as for example sodium hydroxide, potassium hydroxide, aqueous ammonia, Cl-C4-alkyl-amines such as for example triethylamine or hydrochloric acid The salts are usually purified by reprecipitation from water / acetone.
The prodrugs of the compounds of the invention are those which are converted in vivo to the pharmacological active compound. The most common prodrugs are carboxylic acid, esters such as ethyl esters.
Representative peptides are residual peptides. It is understood that the peptide is a radical consisting of 2 to 10 identical or different proteinogenic or non-proteinogenic amino acids. Peptides having 2-5 amino acids are preferred; particularly preferred are those that have 2 amino acids.
The residual amino acids usually mean the radicals of a proteinogenic or non-proteinogenic amino acid. It is understood that non-proteinogenic amino acids are a, b,? and? -aminocarboxylics which may optionally have intermittent substitutions or heteroatoms.
The preferred α-amino acids are -HN- (CH 2) n -CO- with n = 1-10; the - (CH2) n- groups can be branched or unbranched.
Examples of such amino acids are L- and D-amino acids, such as 2-amino-3-hydroxy-4-methylpentanoic acid, 2-amino-3-hydroxy-4-methylpentanoic acid. 2-amino-3-methoxybutanoic acid, 2,3-diaminopropinoic acid, 2-amino-2-methyl-3-hydroxypropanoic acid; 2-amino-2-, methylbtanedioic acid, 2-amino-3-hydroxy-3-methylbutanoic acid, 2-amino-3-hydroxy-3-methylbutanoic acid, 2,3-diaminopropinoic acid, 2-amino-2-methyl acid -3-hydroxypropanoic acid, 2-amino-2-methylbutanedioic acid, 2-amino-2-methylbutanoic acid, 2-amino-2-methyl-4-pentenoic acid, 2-amino-3-methoxypropanoic acid, 1-amino-1 acid -cyclohexanecarboxylic acid, 1-amino-1-cyclopentanecarboxylic acid, 1-aminocyclobutanecarboxylic acid, 1-aminociclopropanecarboxylic acid, 2- (2-furyl) glycine, 2-amino-3-fluorobutanoic acid, 2-aminoisobutanoic acid, 3-chloroalanine, 3 -fluoronorleucine, 3-fluorovaline, 3-fluorolanine, 3-methoxy valine, alpha-cyanoalanine, alpha-methyleucine, beta-chloroalanine, beta-cyanoalanine, beta-hydroxyleucine, beta-hydroxyapartic acid, 3-hydroxyapartic acid, 2-aminobutyric acid, aliglicine, gamma-methyleucine, homoserine, norleucine, norvaline, tert-leucine, 2,3-diaminopropionic acid, 2,3-diaminosuccinic acid, 2-amino acid 4-pentenoic, 2-aminobutyric acid, 2-aminoheptanoic acid, 2-cyclopropyl-2-methylglycine, 4-thiaisoleucine, allotreonin, alpha-methylapartic acid, alpha-methylserine, beta-hydroxynorvaline, beta-methylapartic acid, homocysteine, homoserine, norleucine, 'norvaline, O-methylserine, penicillamine, propargaylglycine, beta-hydroxyapartic acid, vinylglycine, .beta-hydroxyapartic acid, H-4, 5-dehydro-LEU-OH. H-alpha-MeVAL-OH, H-propargayl-GLY-OH, H -allo-ILE-OH, H-PRA-OH, H-trans-4, 5-dehydroLYS-OH, 3-hydroxyapartic acid, 6-hydroxynorleucine , alo-isoleucine, allylic glycine, alpha-amino-butyric acid, gamma-methyleucine, homoserine, norvaline, penicilla ina, ter-leucine, vinylglycine, meso-alpha, beta-diaminosulfonic acid, O-carbonyl-serine, S-methylcystin , 2-amino-2-methylbutanedioic acid, 2-fluoro-beta alanine, beta-alanine, beta-aminobutyric acid, 2,3-dia inosuccinic acid, beta-aminoissbutyric acid, isoserin.
Preferred amino acids are alanine, serine, tryptophan, tyrosine, phenylalanine, threonine, histidine, citrulline, hocysteine, homoserine, hydroxyproline, hydroxymycin, ornithine, sarcosine, tranexamic acid,
(cyclohexylalanine), aminobutyric acid, aminovaleric acid, and aminopropionic acid.
The lower alkyls denote methoxy, ethoxy, pr or toxic, preferably methoxy.
Alkyl usually means linear or branched residual alkyls having from one to six carbon atoms.
Aryl usually means a carbocyclic portion having from 6 to 14 carbon atoms or a heterocyclic portion of 5- or 6-membered having 1, 2 or 3 heteroatoms selected from 0, N, S whose portion may optionally have one or multiple substitutions, with phenyl or substituted naphthyl radicals or unsubstituted radicals that are preferred.
The term "monocyclic portion" is understood to be a saturated or unsaturated ring system having from 3 to 8, preferably from 5 to 7 carbon atoms, which may optionally have one or multiple intermittent heteroatoms such as nitrogen, oxygen or sulfur, particularly a cyclopentyl. cyclohexyl, cycloheptyl, morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropynyl, phenyl, pyridyl, pyrimidinyl, pyridazylnyl, pyrazinyl, furyl, thiophenyl, imidazolium, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, or 1, 2, 4-triazolyl residual. In particular, lower alkyls, alkoxides and halogens are possible substituents.
Preferably, the bicyclic moiety referred to under R5 is a radical such as a naphthyl, tetrahydronaphthyl, decalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, idolyl, benzimidazolyl, indazolyl, oxindolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl or purinyl radical, but particularly a radical indolyl, naphthyl, benzamidazolyl, quinolinyl, tetrahydroquinolinyl, benzothiophenyl, and benzofuranyl.
The term "several" means in connection with monocyclic or bicyclic heteroatoms, preferably one, two or three, more preferably one or two and more preferably the heteroatom is nitrogen.
The term "several" means in connection with substituents or substitution preferably one to five, more preferably one, two or three, more preferably one or two.
Substitutions of monocycles or bicycles in R5 are halogens, nitro, hydroxide, alkoxides, amine, alkylamine, dialkylamine, halogenmethyl, dialogenomethyl, trihalogenomethyl, phosphone, alkylphosphone, dialkylphosphone, S02NH (alkyl), S02N (alkyl) 2, S02 (alkyl) , acetyl, formyl, nitrile, COOH, COOalkyl, -OC (O) alkyl, NHC (O) Oalkyl, OC (O) O-aryl, -NHC (S) NH2, -NHC (S) NHalkyl, -NHC (O) ) -arilo.
Preferred substituents are methyl, ethyl, propyl, isopropyl, halogenyl, especially chlorine, amine, acetyl, alkylammonium, dialkylammonium, alkoxide, hydroxyalkyl, and C0-C alkylcarbonic acids
The preparation of the compounds of general formula (I) is achieved according to methods known per se. Advantageously, the preparation is carried out using the precursors (II), (III) and (IV), respectively.
Where Y represents a carboxyl group, according to the procedure outlined in Schemes 1, 2 and 3.
The compounds of general formula (IV) are novel and useful for the orthogonal synthesis of compounds that include the backbone of structure (IV). The preferred radical for R9 is Fmoc.
Scheme 1
(O (2) (3) («)
i)
^ - e (12)
(10) < l t)
Steps a) to d) in scheme 1 represent the following reactions: a) NaBH3CN / MeOH / RT;
b) PhCOCL / py / DMAP / RT;
c) DBU / toluene / RT / 16 hrs;
d) DIBAL-H / THF / -78 ° C;
Where R6 represents a protected group, for example the benzoyl group, an alkyloxycarbonyl group or the benzylphenylcarbonyl group, and R7 represents hydrogen or a lower alkyl such as methyl, ethyl, propyl, butyl or tert-butyl, R8 represents an alkyl radical or aryl such as a residual methyl, ethyl, trifluoromethyl, phenyl, tosyl or 4-nitrophenyl, but preferably residual methyl or tosyl, and L usually represents a residual sulphonic acid such as methano- or trifluoromethanesulfonic acid or p-acid toluenesulfonic or residual p-toluenesulfonic acid, or halogen such as chlorine, bromine, iodine or acetate.
MHal represents a metal halide such as NaCl, NaBr, Kl, MgCl2 or MgBr2.
The compounds of formula (5) have been described
(J.O.C. 48, 1129-31 (1983)). The conversion of a fatty alcohol to (5) a sulphonic or an ethic ester of formula (6) is carried out according to standard procedures. The conversion of an alcohol of formula (5) to a halide of formula (6) using N-chloro-, N-bromo- or N-iodosuccinamide (NCS, NBS, NIS) in the presence of triphenylphosfosine (Ph3P) is executed in analogy to the corresponding procedures of the literature (for example, Tetrahedrom Asy. 4 1619-2 A (1993)). The decarboxylation of manolic esters using metal halides in DMSO at elevated temperatures is well known. (T.L. 957 (1973)). The compounds of formula (9) have been described (JACS 114 7324-25 (1992)). The epoxy opening of a compound of formula (10) resulting in an alelic alcohol of formula (11) is carried out in analogy to the literature (Tetrahedron 2_4, 5827-30 (1968)). The conversion of a compound of formula (13) to a compound of general formula (II) by means of a rearrangement of Claisen is performed analogously to the literature (Tetrahedron 52, 941-54 (1996)).
Scheme 2
c) Ph (16)
(19) (18) (17)
Steps a) through f) in scheme 2 represent the following reactions: a) Ac20 / pyridine / DMAP
b) 4 N HC1 / 16 hrs; (14) / EtN (i-Pr) 2
c) (16), R7 = Et / HMDS / n-BuLi / -78 ° C
d) 1 N HC1 / THF / RT / 30 minutes
e) Boc20 / etN (i-Pr) 2 / acetonitrile / 16 hrs
f) LiOH / THF-MeOH-H20
Where R6 and R7 have the meanings mentioned above.
Scheme 3
(16) (6) (20) (21)
Steps a) through e) in Scheme 3 represent the following reactions:
a) HDMS / n-BuLi / -78 ° C
b) CH3COOH / THF / RT / 30 minutes
c) R9Cl / EtN (i-Pr) 2 / THF / 16hrs
d) 4 N HCl / dioxane
e) EtN (i-Pr) 2 / acetonitrile
Where Re and R7 have the meanings mentioned above and R9 represents another protected group such as Fmoc or Troc.
The compounds of formula (I) can be administered in solid or liquid form or as aerosols on the oral, enteral, parenteral, topical, pulmonary or rectal routes in all pharmaceutically acceptable non-toxic carriers, auxiliaries and additives. The compounds of formula (I) can also be applied locally on / within the bones (optionally with surgical operation). The term "parenteral" includes delivery of subcutaneous, intravenous and intramuscular infusions. The forms of oral administration may be, for example, tablets, capsules, coated tablets, syrups, solutions, suspensions, emulsions, elixirs, etc., which may contain one or more additives from the following groups eg, flavoring substances, sweeteners , and condoms. The oral administration forms contain the active agent together with pharmaceutically acceptable non-toxic carriers suitable for the production of tablets, capsules, coated tablets, etc., such as calcium carbonate, sodium carbonate, sodium or sodium phosphate, starch. , mannitol, methylcellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids (such as astearic acid), peanut oil, olive oil, paraffin, Miglyol, gelatin, agar agar, magnesium stearate, beeswax , cetyl alcohol, lecithin, glycerol, animal and vegetable fat, solid polymers of high molecular weight (such as polyethylene glycols). Tablets capsules, coated tablets etc, may be provided with an appropriate cover such as monoestereate glyceride or glyceride distereate, as well as prevent unwanted side effects in the stomach, or result in prolonged activity due to delayed absorption in the gastrointestinal tract. Aqueous or oily sterile injectable solutions or suspensions are preferably used in an injectable medium, containing common additives such as stabilizers and solubilizers. Such additives may be for example, water, isotonic saline, 1,3-butanedidol, fatty acids (such as oleic acid) mono- and diglycerides, or Miglyol. For rectal administration, all suitable non-irritating additives can be used that are solid at normal temperatures and liquids at rectal temperature. Such as cocoa butter and polyethylene glycol. For aerosol administration, the common pharmaceutical carrier media are used. For external applications, creams, tinctures, gels, solutions or suspensions are used with the pharmaceutically common additives the dose may depend on several factors such as the mode of application, species, age and / or conditions of the individual. The doses administered daily or at intervals are around 1-1000 mg / person, preferably around 10-250 mg / person and can be ingested continuously or distributed several times.
The compounds of formula (I) can be applied locally on / within the bones (optionally with surgical operation). The application directly on / within the bones (optionally with surgical operation) can be carried out any solution or suspension, conveniently by infusion or injection, locally or by allocating a carrier. For example, target compound carriers of formula (I) can be applied as gels, pastes, solids or as coatings or implants.
Biocompatible materials and preferably biodegradable materials are used as carriers. Preferably the materials are added materials that induce wound healing or osteogenesis.
For local application it is preferred to introduce the compounds of formula (I) into gels or polymeric films, and thereby immobilize them, and to apply these preparations directly on the point of the bone to be treated. These gels based on polymers or films consist, for example, of glycerol, methylcellulose, hyaluronic acid, polyethylene oxides and / or polyoxazoles. Collagen, gelatin and alginates are also suitable and are described in WO 93/00050 and WO 93/20859, for example. Other polymers are polylactic acid (PLA) and copolymers of lactic acid and glycolic acid (PLPG) (Hollinger et al., J. Bio ed, Mater.
Res 37, 71.82 (1983)), and the "demineralized bone matrix"
(DBM) derived from bone (Gunterman et al, Kollagen Reí. Res _8, 419-4319 (1988)). Polymers such as those used for the adsorption of TGFB, for example are also suitable and are described in EP-A 0,6161,814 and EP-A 0,567,391 as well as synthetic bone matrices according to WO 91/18558.
Materials commonly used in the implantation of bone substitutes or other active therapeutic substances are also suitable as carriers for the compounds of formula (I). Such carriers are also based on, for example, calcium sulfate, tricalcium phosphate, hydroxylapatite and their biodegradable derivatives, and polymers. Apart from these biodegradable carriers, those non-biodegradable carriers that are biocompatible are suitable. For example, these carriers are synthetic hydroxylapatite, bioglass, aluminates or other ceramic materials (for example calcium aluminate phosphate). Preferably these materials are used in combination with said biodegradable materials, such as, in particular, polylactic acid, hydroxylapatite, collagen, or tricalcium phosphate. Other non-degradable polymers have been described in US Patent 4,164,560, for example. Particularly preferred is the use of carriers that continuously release the compound of formula (I) at the site of action. Especially suitable for this purpose are, for example, "slow release spheres" from Innovative research of America, Toledo, Ohio, USA. Particularly preferred is the use of spheres which release the compound of formula (I) for several days, preferably up to 100 days in a daily dose of 1-10 mg / kg per day.
Apart from the compounds mentioned in the examples, and the compounds which can be derived by the combination in all senses of the substituents mentioned in the claims, the following derivatives, as well as their pharmaceutically acceptable salts, particularly the hydrochlorides and trifluoroacetates are preferred in the sense of the present invention.
Index of abbreviations used:
Aba = aminobutyric acid
Ac = acetyl
Ada = (l-midino-2,5-dihydro-lH-pyrrol-3-yl) alanine
Ala = alanine
Ava = aminovaleric acid
Bn = benzyl
Boc = tert-butyloxycarbonyl
Bu = butyl
Cbz = benzyloxycarbonyl
Cha = cyclohexylalanine
DBU 1, 8-diazabicyclo [5. 4. 0] undec-7-ene DIBAL-H = diisobutylaluminum hydride
DMAP = 4-dimethylaminopyridine DMF di ethylformamide Et = ethyl Fmoc = 9-fluorenylmethoxycarbonyl
Gly = glycine HMDS = hexa ethyldisilazane i-PR isopropyl Me methyl NMM = N-methylmorpholine Ph phenyl Phe = phenylalanine Pro proline Py pyridine RT room temperature Ser septa t-but = tert-butyl TBTU tetrafluoroborate 2-H1-bemzotriazole-1- il) -1,1,3, 3-tetramethyluronium
TCP = trityl chloride-polystyrene
THF = tetrahydrofuran
Thr = threonine
Troc = 2,2, 2-trichloroethoxycarbonyl
Trp = tryptophan
Tyr = tyrosine
= residence time
Val = valina
In addition, the one-letter code for amino acids is used.
Within the meaning of the present invention, the following mimetic peptides are preferred in addition to the compounds mentioned in the examples and compounds that can be derived by the combination in all senses of the substituents mentioned in the claims in the preferred compounds.
Preferred compounds:
1) Acid 2-. { 5- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (indol-2-yl) -propionic. 2) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (7-methyl-indol-2-yl) -propionic) 2- Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-benzo [b] thiophen-2-yl-propionic 4) 2- Acid. { 5- [Amino-3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (6-Methyl-indol-2-yl) -propionic 5) 2- Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2-5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (6-hydroxy-indol-2-yl) -propionic 6) 2- Acid. { 5- [2-Amino-3-l (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3-methyl-indol-2-yl) -propionic 7) 2- Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3-methyl-benzafuran-2-yl) -propionic 8) 2- Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3, 4-dimethyl-benzofuran-2-yl) -propionic acid 9) 2- acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,5-dimethylbenzofuran-2-yl) -propionic acid. 10) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propioylamino] -pentanoylamino} -3- (3, 6-dimethyl-benzofuran-2-yl) -propionic acid. 11) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanylamino} -3- (5-ethyl-3-methylbenzofuran-2-yl) -propionic acid. 12) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} 3-hydroxy-3- (3-methyl-benzofuran-2-yl) -propionic acid. 13) - Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3, 7-dimethylbenzafuran-2-yl-propionic acid.
14) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (7-ethyl-3-methyl-benzofuran-2-yl) -propionic acid. 15) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3, 6-dimethylbenzofuran-2-yl) -3-hydroxy-propionic acid. 16) Acid 2-. { 5- [2-Amino-3- (l-carbamimidyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,5-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 17) Acid 2-. { 5- [2- (Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,4-dimethylbenzofuran-2-yl) -3-hydroxy-phoxypic-18) 2- Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,7-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 19) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (7-Chloro-3-methylbenzofuran-2-yl) -3-hydroxy-propionic acid.
) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (5-ethyl-3-methyl-benzofuran-2-yl) -3-hydrox-propionic acid. 21) 2- Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- . { 7-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 22) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-furan-2-yl-pxopionic. 23) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamines] -pentanoylamino} -3-furan-2-yl-3-hydroxypropionic acid. 24) Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -thiophen-2-yl-acetic. 25) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-thiophene-2-yl-propionic acid. 26) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylimino] -pentanoylamino} -3- (pyrrol-2-yl) -propionic.
27) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (5-methyl-thiophen-2-yl) -propionic acid. 28) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-hydroxy-3- (5-methyl-thiophen-2-yl) -propionic acid. 29) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (5-ethyl-thiophen-2-yl) -propionic acid. 30) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (5-propyl-thiophen-2-yl) -propionic. 31) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbaminidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (5-Dihydroxymethyl-furan-2-yl) -propionic acid. 32) 5- (2- { 5- [2-Amino-3- (l-carbamimido-2, 5-dihydro-pyrrol-3-yl) -porpionylamino] -pentanoylamino} -2-carboxylic acid ethyl) -2-methyl-furan-3-carboxylic acid. 33) 5- (2- { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] pentanoylamino.) -2-carboxy-ethyl) -2-ethyl-furan-3-carboxylic acid.
34) 5- (2-. {5- [2-Amino-3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino] -2- ethyl ester. -carboxy-ethyl) -2-methyl-pyrrole -3-carboxylic acid. 35) 5- (2- { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino.} -2-carboxy-ethyl) -2-propyl-furan-3-carboxylic acid. 36) 3- (5-Acetylimino-4,5-dihydro-thiophen-2-yl) -2-i5- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) acid ) -propionylamino] -pentanoylamino} -3-hydroxy-propionic. 37) Acid 5-. { 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -2-carboxy-ethyl) -2-isobutyl-furan-3-propionic. 38) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-cyclopentane-1-enyl-propionic acid. 39) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-hydroxy-3-thiophen-2-yl-propionic acid.
40) Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} - (3-methyl-benzo [b] thiophen-7-yl) -acetic. 41) Acid-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -phenyl-acetic. 42) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro, pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,4-dihydroxy-phenyl) -3-hydroxy-propionic acid. 43) Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydroxy-pyrrol-3-yl) -propionylamino] -pentanoylamino} - (4-hydroxy-phenyl) -acetic. 44) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydroxy-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-phenyl-butyric. 45) Acid 2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydroxy-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3- (3,4-bis-benzyloxy-phenyl) -3-hydroxy-propionic acid. 46) - Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} - 3-hydroxy-succinic.
47) 2- ( { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino acid .}. -carboxymethyl) -benzoic acid. 48) 5- [2-Amino-3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino acid} - (3-oxo-2, 3-dihydro-isoxasol-5-yl) -acetic .. 49) Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl.}. -propionylamino] -pentanoylamino-cyclohexyl-acetic acid.
50) 1,4-dienyl acid. { 5- [2-Amino-3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl). Propionylamino] -pentanoylamino} -cyclohexa-1, 4-dienyl-acetic acid. 51) 1,5-dienyl acid. { 5- [2- (2-Amino-3-hydroxy-butyryl-ino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -cyclohexa-l, 5-dienyl-acetic acid. 52) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-hydroxy-3-pyridine-3-yl-propionic acid. 53) Acid -2-. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -3-hydroxy-3-pyridine-4-yl-propionic acid.
54) 4- ( { 5- [2-Amino-3- (1-carbamimidoi'-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} -carboxymethyl) -2-hydroxybenzoic. 55) 4- ( { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino acid .}. -carboxymethyl) -benzoic acid. 56) Acid 2-. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} 3-phenylsulfanyl-butyric. 57) Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} - (tetrazol-5-yl) -acetic. 58) Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} - (indol-3-yl) -acetic, 59) Acid. { 5- [2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propylamino] -pentanoylamino} - (3,4-dihydroxy-phenyl) -acetic. 60) Acid. { 5- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -pentanoylamino} - (3, 5-dihydroxy-phenyl) -acetic 61) 2- Acid. { 4- [2-Amino-3- (l-carbamimidoyl-2, 5-hydroxy-phenol-3-yl) -propionylamino] -butyrylamino] -3- (indol-2-yl) -propionic acid. 62) Acid 2-. { 4- [2- (2-Amino-3-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (7-methyl-indol-2-yl) -propionic. 63) Acid 2-. { 4- [2-Amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-benzo [b] thiophen-2-yl-propionic acid. 64) Acid 2-. { 4 - [- 2- (2-Amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (6-methyl-indol-2-yl) -propionic. 65) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (6-hydroxy-indol-2-yl) -propionic acid. 66) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butylamino} -3- (3-methyl-indol-2-yl) -propionic. 67) - Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3-methyl-benzofuran-2-yl) -propionic acid.
68) Acid 2-. { 4- [2- (2-amino-3-hydro-butylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butylamino} -3- (3, 4-dimethyl-benzofuran-2-yl) -propionic acid. 69) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino-butylamino} -3- (3, 5-dimethyl-benzofuran-2-yl) -propionic acid. 70) Acid 2-. { 4-J2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 6-dimethyl-benzofuran-2-yl) -propionic acid. 71) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-ethyl-3-methyl-benzofuran-2-yl) -propionic acid. 72) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxy-3- (3-methyl-benzofuran-2-yl) -propionic acid. 73) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 7-dimethyl-benzofuran-2-yl) -propionic acid. 74) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (7-ethyl-3-methyl-benzofuran-2-yl) -propionic acid.
75) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 6-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid.
76) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 5-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 77) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 4-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid.
78) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 7-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 79) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (7-Chloro-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 80) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid.
81) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (7-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid. 82) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-furan-2-yl-propionic. 83) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-furan-2-yl-3-hydroxy-propionic acid. 84) Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -thiophen-2-yl-acetic.
85) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-thiophene-2-yl-propionic acid. 86) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (pyrrol-2-yl) -propionic. 87) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-methyl-thiophen-2-yl) -propionic acid.
88) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxy-3- (5-methyl-thiophen-2-yl) -propionic acid. 89) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-ethyl-thiophen-2-yl) -propionic acid. 90) Acid 2-. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-propyl-thiophen-2-yl) -propionic. 91) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (5-hydroxymethyl-furan-2-yl) -propionic acid. 92) 5- (2- { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino.) -2-carboxy-ethyl) -2-methyl-furan-3-carboxylic acid. 93) 5- (2-. {4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -2-carboxylic acid ethyl) -2-ethyl-furan-3-carboxylic acid. 94) - 5- (2-. {4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) ethyl ester ) -propionylamino] -butyrylamino.} -2-carboxy-ethyl) -2-methyl-pyrrole-3-carboxylic acid.
95) 5- (2-. {4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -2-carboxylic acid ethyl) -2-propyl-furan-3-carboxylic acid. 96) 3- (5-Aoethylimino-4, -dihydro-thiophen-2-yl) -2- acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxá-propioni or
97) 5- (2- {4.4 { 2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino acid} -2- carboxy-ethyl) -2-isobutyl-furan-3-carboxylic acid 98) 2- Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- cyclopent-1-enyl-propi or co 99) 2- Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrole-3-yl]) -propylamino] -butylamino} -3-hydroxy-3-thiophen-2-yl-propionic acid 100) Acid. { - [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoi 1-2, 5-dihydro-pi-pyr-3-y1) -propionyl-mino] -butyrylamino} - (3-methyl-benzo [b] thiophen-7-yl) -acetic 101) Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -phenyl-acetic 102) 2- Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyralmino} -3- (3,4-dihydro-phenyl) -3-hydroxypropionic acid 103) Acid. { 4- [2-amino-3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylami o} - (4-hydroxy-phenyl) -acetic 104) 2- Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-phenyl-butyric
105) Acid 2-. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3- (3, 4-bis-benzi loxi-phenyl) -3-hydroxy-propionic acid 106) 2-. { 4- [2-. { 2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2), 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxy-succinic 107) 2- ( { 4- [2-amino-3- (l-carbamimidoyl-2,5-di-idro-pyrro] -3-yl) -propi or lamino] - butylamino.}. -carboxymethyl) -benzoic acid 108 '5- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoi 1-2, 5-dihydro-pyrrole-3-- il) -propionylamino] -bptyrylamino} - (3-oxo-2,3-dihydro-isoxazol-5-yl) -acetic-109) Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -cyclohexyl-acetic acid 110). { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino} -butyrylamino} -cyclohexa-l, 4-dienyl-acetic 111) Acid. { 4- [2-amino-3- [l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -cyclohexa-1, 5-dienyl-acetic 112) 2- Acid. { 4- [2- (2-amino-3-hydroxy-butyryl-ino) -3- (l-carbamimidol-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxy-3-pyridin-3-yl-propionic 113) 2- Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-hydroxy-3-pyridin-4-yl-propionic acid 114) 4- (. {4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2, 5 -dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino.} - carboxymethyl) -2-hydroxy-benzoic acid 115) 4- (. {4- [2-amino-3- (l-carbamimidoyl -2,5-dihydro-pyrrole -3-y1) -propioni mino] -butyrylamino.} - carboxymethyl) -benzoic acid 116) 2- Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} -3-phenylsulfanyl-butyric 117) Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} - (tetrazol-5-yl) -acetic 118) Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} - (indol-3-il) -acetic
119) Acid. { 4- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} - (3,4-dihydroxy-phenyl) -acetic 120) Acid. { 4- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -butyrylamino} - (3, 5-dihydroxy-phenyl) -acetic 121) 2- Acid. { 3- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (indol-2-yl) -propionic 122) 2- Acid. { 6- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} -3- (7-methyl-indol-2-yl) -propionic 123) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl) -2,5-dihydro-pyrrol-3-yl) -propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3-benzo [b] thiophen-2-yl-propionic acid
124) Acid 2-. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (6-methyl-indol-2-yl) -propionic 125) 2- Acid. { 6- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} -3- (6-hydroxy-indol-2-yl) -propionic 126) 2- (2-. {2- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrole-3) acid -yl) -propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3- (3-methyl-indol-2-yl) -propionic 127) 2- Acid. { 3- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (3-methyl-benzofuran-2-yl) -propionic 128) 2- (2- { 2- { 2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrole) -3-yl) -propionylamino.} - 3-hydroxy-propionylamino.]. -propionylamino) -3- (3,4-dimethyl-benzofuran-2-yl) -propionic 129) 2- Acid. { 6- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidol-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} -3- (3, 5-dimethyl-benzofuran-2-yl) -propionic 130) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l -carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -3-hydroxy-propionylane, no.}. -propionylamino) -3- (5-ethyl-3-methyl-benzofuran-2-yl) - propionic 131) Acid 2-. { 3- [2-amino-3- (l-carbamimidol-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-hydroxy-3- (3-methyl-l-benzofuran-2-yl) -propionic acid
132) 2- (2- { 2- [2- (2-amino-3-hydroxy-bpyrylamino) -3- (-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionic acid ] -3-hydroxy-propionylamino.} - propionylamino) -3- (3,7-dimethyl-benzofuran-2-yl) -propionic acid 133)? - acid? { 6- [2-am no-3- (l-carbamimidoyl-2, -dihydro-pi rrol -3-i 1) -propioni l mino] -hexanoi lo-3- (7-eti1 -3-meti 1-benzofuran -2-i 1) -propane 134) 2- (2- { 2- [2- (2-amino-3-hydroxy-bptylamino) -3- (_ -carbamimidoi 1-2, 5-dihydro) acid -pyrrole -3-i 1) -pro i ni 1 ami no] -3-nor droxi-propy nylo n.}. -propionylamino) -3- (3,6-dimethyl-benzofuran-2-yl) -3- hydroxy-propioni co 135) 2- Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (3, 5-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid
136) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoi 1-2, 5-dihydro-pi-3-yl) - propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3- (3,4-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid 137) 2- Acid. { 6- [2-amino-3- (1-carbamimidoi 1-2, -dihydro-pyrrol-3-yl) -propionyl-mino] -hexanoyl} -3- (3,7-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid
138) 2- (2- {2. {2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamyl-dodecyl-2,5-dihydro-pyridyl) -3- il) -propy or lamino] -3-hydroxy-propionylamino or.}. -propionylamino) -3- (7-chloro-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid 139) Acid? . { 3- [2-amino-3- (1-carbamimidoi -2, -dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (5-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propy ni co 140) 2- Acid. { 6- [2- (2-amino-3-hydroxy-bufrylamino) -3- (-carbamimi doi 1 -2,5-dihydro-pyrrol-3-yl) -propioni 1 amino] -hexanoi lamino} -3- (7-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic acid 141) 2- Acid. { 6 [2-amino-3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoyl} -3-furan-2-yl-propionic 142) 2- Acid. { 3- [2-. { 2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-furan-2-yl-3-hydroxy-propionic 143) Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -thiophen-2-yl-acetic acid 144) 2- (2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) acid) -propionylamino] -3-hydroxy-propionylamino.}. -propionylamino) -3-thiophen-2-yl-propionic 145) 2- Acid. { 6- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoyl} -3- (pyrrol-2-yl) -propionic 146) 2- Acid. { 3- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (5-methyl-thiophen-2-yl) -propionic 147) 2- (2 { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl- 2, 5-dihydro-pyrrol-3-yl) -propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3- (5-ethyl-thiophen-2-yl) -propionic 148) 2- Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3- (5-propyl-thiophen-2-yl) -propionic 149) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l- carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3- (5-hydroxymethyl-furan-2-yl) -propionic 150) 5- Acid (2- { 6- { 2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino.} -2-carboxy-ethyl) - 2-methyl-furan-3-carboxylic acid 151) 5- (2- (2-. {2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2, 5) acid -dihydro-pyrrol-3-yl) -propionylamino] -3-hydroxy-propionylamino.}. -propionylamino) -2-carboxy-ethyl) -2-ethyl-furan-3-carboxylic 152) ethyl ester of 5- ( 2- {3- [2-amino-3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -2-carboxy-ethyl) -2-methyl -pyrrole-3-carboxylic acid 153) 5- (2-. {6- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrole-3) acid -yl) -propionylamino] -hexanoylamino.} -2-carboxy-ethyl) -2-propyl furan-3-carboxylic 154) 5- (2-. { 3- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -2-carboxy-ethyl) -2-isobutyl-furan-3-carboxylic acid 155) (2- {2- [2-amino-3- (l-carbamimidoyl-2, 5-dihydro-pyrrole-3-} il) -propionylamino] -3-hydroxy-propionylamino.}. -propionylamino) -3-cyclopent-1-enyl-propionic 156) 2- Acid. { 3- [2-. { 2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-hydroxy-3-thiophen-2-yl-propionic 157) 2- Acid. { 6- { 2-amino-3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} -3- (3, -dihydroxy-phenyl) -3-hydroxy-propionic 158) 2- Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-phenyl-butyric 159) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrole-3) acid -yl) -propionylamino] -3-hydroxy-propionylamino.]. -propionylamino) -3- (3,4-bis-benzyloxy-phenyl) -3-hydroxy-propionic acid. 160) 2- Acid. { 6- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} -3-hydroxy-succinic 161) Acid. { 3-. { 2-amino-3- (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -cyclohexa-1,4-dienyl-acetic 162) 2- Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-hydroxy-3-pyridin-3-i1-propionic acid 163) 4- (. {6- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) - propionylamino] -hexanoylamino.} - carboxymethyl) -2-hydroxy-benzoic 164) 2- Acid. { 3- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -3-phenylsulphane-butyric 165) Acid. { 6- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -hexanoylamino} - (indol-3-yl) -acetic 166) Acid. { 3- [2-amino-3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} - (3, 5-dihydroxy-phenyl) -acetic 167) Acid (2. {2- 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl) -propionylamino] -propionylamino.]. -propionylamino) -3- (6-hydroxy-indol-2-yl) -propionic 168) (2- [2- [2-amino-3- (l -carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.}. -propionylamino) -3- (3,6-dimethyl-benzofuran-2-yl) -propionic 169) 2- ( 2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino}. propionylamino) -3- (3,4-dimethyl-benzofuran-2-yl) -3-hydroxy-propionic acid 170) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino ) -3- (l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.}. -propionylamino) -3- (7-ethyl-3-methyl-benzofuran-2-yl) -3-hydroxy-propionic 171) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyryl-ino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol- 3-yl) -propionylamino] -propionylamino .}. -propionylamino) -3-thiophen-2-yl-propionic 172) 2- (2-. { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -propionylamino) -3- (5-methyl-thiophen-2-yl) -propionic 173) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- ( l-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.]. -propionylamino) -3- (5-hydroxymethyl-furan-2-yl) -propionic 174) Acid 3- (5 -acetylimino-4,5-dihydro-thiophen-2-yl) - (2-. {2- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] ] -propionylamino.}. -propionylamino] -3-hydroxy-propionic 175) (2- {2- [2- { 2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl- 2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} -propionylamino) -phenyl-acetic acid 176) (2- {2- [2-amino-3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -p-sprylamino] -propionylamino} acid. -propionylamino) -3- (3,4-dihydroxy-phenyl) -3-hydroxy-propionic acid 177) 2- (2- { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3 acid - (1-carbamimidoyl-2, 5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.]. -propionylamino) -3- (3, 4-bis-benzyloxy-phenyl) -3-hydroxy-propionic acid. ) 2- ((2- {2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] acid] -propionylamino.} - propionylamino) -carboxymethyl) -benzoic acid 179) 2- (2- { 2- [2- (2-amino-3-hydroxybutyrylamino) -3- (l-carbamimidoyl- 2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.} - propionylamino) -3-hydroxy-3-pyridin-4-yl-propionic acid 180) Acid (2-. {2- 2- [2 - (2-amino-3-hydroxy-butyrylamino) -3- (l-carba? Aidoido-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino.} - propionylamino) - ( tetrazol-5-yl) -acetic 181) Acid (2-. { 2- [2- (2-amino-3-hydroxy-butyrylamino) -3- (1-carbamimidoyl-2,5-dihydro-pyrrol-3-yl) -propionylamino] -propionylamino} - propionylamino) - (3,4-dihydroxy-phenyl) -acetic
The following examples exemplify variants for the synthesis of the compounds of the invention. The structure of the compounds was obtained by ^? -, 13C-RM-s spectroscopy and optionally by mass spectroscopy. The purity of the substances was obtained by analysis of C, H, N and by chromatography.
Example 1
(±) -3- (2-tert-butoxycarbonyl-amino-2-hydroxycarbonyl) -ethyl-2,5-dihydropyrrole-l- (N, N'-di-tert-butoxycarbonyl) carboxy idine tBoc-Ada (Bos) 20H]
a) 1-tert-Butyl ester 3-ethyl ester of 4-oxo-pyrrolidine-1,3-dicarboxylic acid
(J. COOPER et al., J. Chem. Soc. Perkin Trans. 1, 1993t 1313-1318)
To a reflux suspension of 1.58 g (66 mmol) of sodium Jiidride in 100 ml THF was added dropwise a solution of 12.79 g (60 mmol) of N-etrt-butyloxycarbonyl-glycine ethyl ester and 7.15 g (66 g). mmol) of ethyl acrylate in
100 ml of THF. After the addition was complete the mixture was heated to reflux for 2 h additional. The clear solution was cooled to room temperature, poured into 100 ml of ether / 100 ml of water and acidified under vigorous stirring with IN hydrochloric acid with methyl orange. The layers were separated and the aqueous layer was extracted three times with ether. The combined organic phases were washed with saturated sodium bicarbonate in water and brine, dried with MgSO 4 and evaporated. Short path distillation of the residue gave 10.92 g (71%) of 1-tert acid.
Butylester 3-ethyl ester 4-sxo-pyrrolidine-1,3-dicarboxylic acid as a colored oil, p.fus 119-112 ° C (0.2 mbar), which solidifies in a prolonged stay in the refrigerator.
GC / MS (HP 5890 11/5972;, column: HP 5, film thickness 30 mx 25 mm x 0.25 Om, carrier gas: helium, temperature gradient: 50 ° C, 3 min, then with 20 ° C / min at 250 ° C) tR = 9.68 min
m / z [%] = 185 (2), 130 (10), 112 (18), 85 (6), 57 (100).
b) 1-tert. -butyl-3-ethyl ester of the acid-hydroxy-pyrroline-1,3-dicarboxylic acid
To a solution of 5.15 g (20 mmol) of 4-oxo acid 1-tert-butyl ester 3-ethyl ester pyrrolidine-1,3-dicarboxylic acid in 30 ml of methanol was added to 1.88 g (30 mmol) of sodium cyanoborohydrate and small amounts of methyl orange. The pH was adjusted to 3 with stirring by the dropwise addition of hydrochloric acid IN (the color changes from yellow to orange). After no more acid was consumed, the mixture was stirred for one hour. The solvent was evaporated in vacuo and the residue was partitioned between a-cetate and water. The organic layer was washed twice with water then with brine, dried over magnesium sulfate and evaporated. The residual yellow oil was used in the next step without any further purification.
GC / MS ((HP 5890 11/5972;, column: HP 5, film thickness 30 x 25 mm x 0.25 Dm, carrier gas: helium, temperature gradient: 50 ° C, 3 min, then 20 ° C / min at 250 ° C) tR = 12.44 min (without separation of diastereomers)
m / z [%] = 259 (M, 0.3), 241 (0.7), 202 (5), 186 (7),
158 (10), 112 (14), 68 (31), 57 (100).
s) 1-tert. 4-Benzoyloxy-pyrrolidine-1,3-dicarboxylic acid 3-ethyl ester
To a solution cooled with 1-tert ice. 3-ethyl ester of the 4-hydroxy-pyrrolidine-1,3-dicarboxylic acid of the reduction described above and 244 mg (2 mmol) of DMAP in 40 ml of pyridine were added dropwise 3.51 g (25 mmol 9 of benzoyl chloride) After the addition was complete, the ice bath was removed and the mixture was stirred at room temperature for 2 h.The mixture was diluted with ethyl acetate and poured onto ice.The organic layer was separated, washed with Water CuS04 saturated in water, water and brine, dried over MgSO4 and evaporated The residual yellow oil was used the next step without further purification.
GC / MS ((HP 5890 11/5972;, column: HP 5, film thickness 30 x 25 mm x 0.25 Dm, carrier gas: helium; -temperature gradient: 50 ° C, 3 min, then at 20 ° C / min at 250 ° C) tR = 17.28 min and 17.38 min (1: 1 mixture of cis / trans isomers)
m / z [%] = 318 (0.1), 290 (5), 262 (2), 241 (2), 185 (29), 141 (10), 112 (23), 105 (53), 77 (27 ), 68 (100), 57 (97).
d) 1-tert. -butyl ester 3-ethyl ester of 2,5-dihydro-pyrrole-l, 3-dicarboxylism
To a 1-tert solution. The crude 3-ethyl ester of 4-benzoyloxy-pyrrolidine-1,3-dicarboxylic acid of the benzolation described above in 75 ml of dry toluene was added 4.11 g (27 mmol) of DBU. The opaque heterogeneous mixture was stirred at room temperature for 16 h. After this time the original material was not detected by analysis with TLC and GC. The mixture was filtered through a short column of silica (eluted with petroleum ether / ethyl acetate 1: 1) and evaporated. Bulb-to-bulb distillation of the slightly yellow residual oil gave 4.16 g (86%) of 2,5-dihydro-pyrrole-1,3-dicarboxylic acid 1-tert.-butylester 3-ethyl ester as a b.p. 110 ° C / 0.2 mbar, which solidified slightly in a waxy mass while in the refrigerator.
GC / MS ((HP 5890 11/5972; column: HP 5, film thickness 3-0 - yes x 25 mm x 0.25 O, carrier gas: helium;
Temperature gradient: 50 ° C, 3 min; then with 20 ° C / min at 250 ° C) tR = 11.94 min m / z [%] = 241 (M, 1.4), 196 (0.4), 185 (11), 168 (11), 140 (14), 112 (17), 68 (24), 57 (100)
^ -NMRÍCDCla, 300 MHz)
d = 1.27 (t, = 7.1 Hz, 3H, OCH2CH3), 1.43, 1. 4 I2s,
9H, C (CH3) 3] / 4.25 (d, j = 7.1 Hz, 2H, OCH? CHs), 4.15-4.27 (br.
M, 4H7 2-H, 5-H), 6.66-6.71 (m, iH, 4-H) ppm. Double comma means due to impediment rotation.
134 C-NMR (CDCL3 / .75MHZ)
d = 14.16, 14.20 (q, -CH2-CH3) ", 28.45 [q, -C (C (CH3) 3]
51. 715.51.39, 53.62, 53.84 (4t, C-2, C-5) ", 60 69 (t-CH2-CH3) 79.84 [s, - (CH3) 3], 132.29 (s, C-3), 136.44 , 136.55 (2d, C-4) ", 153.86, 154.08 (2s, -NCOO -) *, 162.75 (s, COOEt) ppm
e) 1-tert.butyl ester of 3-hydroxymethyl-2,5-di-hydro-pyrrole-1-carboxylic acid
To a solution of 5.43 g (22.5 mmol) of 1-tert. -butyl ester 3-ethyl ester of 2,5-dihydro-pyrrole-1,3-dicarboxylic acid in 50 ml of THF, cooled to -78 ° C were added dropwise 50 ml of a solution of DIBAL-H IN in hexane. The mixture was allowed to warm to room temperature overnight. As the TLC analysis indicated the total consumption of the original material, the mixture was cooled in an ice bath and 1.90 g of water were cautiously added, followed by 1.90 g of aqueous NaOH and 5.70 g of water. The white precipitate was filtered, thoroughly washed with ether and the combined filtrates were evaporated, the bulb-to-bulb distillation of the residual pale yellow oil yielded 4.13 g (93%) of 3-hideroxymethyl-2, 5-dihydro tert-butylester. -pyrrole-1-carboxylic acid as a bp coloring oil 130 ° C (0.2 mbar).
GC / MS (HP 5890 11/5972;, column: HP 5, film thickness 30 mx 25 mm x 0.25 ™ carrier gas: helium, temperature gradient: 50 ° C, 3 min, then with 20 ° C / min 250 ° C) tR = 11.34 min
m / z [%] = 199 (M, I), 143 (10), 142 (13), 126 < 13), 112 (12), 80 (10), 68 (45), 57 (100)
^ -NMR (CDC13, 300 MHz)
d = 1.44 (s, 9H.t-Bu), 4.09 (br, m.4H, 2-H, 4-H), 4.18 (br.S, 2H, CH20H), 5.63 (br.D, 1H, 4 -H) ppm.
13 C-NMR (CDCI3, 75 MHz)
d = 28.5 [q, C (CH3) 3], 52.8, 53.0, 53.2, 53.3 (4t, C-2, C-5) ", 57.7, 59.8 (2d, CH2OH), 79.5 [s, C (CH3) 3], 120.0, L2Ü_3. &C-J, 135.6 (s, C-3), 154-4 (s, COOtBu) ppm.
"Double set of signs means impeded rotation.
f) Ter-butyl ester of 3-acetoxymethyl-2,5-dihydro-pyrrole-1-carboxylic acid.
To a solution of 4.13 g (20.7 mmol) cooled with ice of the 3-acetoxymethyl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butylester and 244 mg (2 mmol) of DMAP in 50 ml of pyridine were Aggregates 3.06 (30 mmol) of acetic anhydride, the mixture was stirred for 30 min. At 0 ° C then for 60 jain at room temperature. The mixture was drained on ice and extracted twice with ether, washed with saturated CuS04, water and brine and dried over MgSO4. Bulbo-bulb evaporation gave 4.82 g (97%) of the 3-acetoxymethyl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester as a colorless oil, b.p. 105 ° C (0.2 mbar).
GC / MS (HP 5890 11/5972;, column: HP 5, film thickness 30 mx 25 mm x 0.25 pm carrier gas: helium, temperature gradient: 50 ° C, 3 min, then with 20 ° C / min 250 ° C) tR = 11.87 min
m / z [%] = 241 (M ", 0.2), 226 (0.1), 185 (5), 166 (5), 125 (18),
108 (3), 81 (13), 180 (23), 57 (100)
1H-NMR (CDC13, 300 MHz) d = 1.43.1.44 [2s, 9H, C (CH3) 3] *, 2.04, 2.06 (2S.3H, OOCCH3) *, 4.05-4.12 (br.m, 4H, 2 -H, 5-H), 4.61 (br.d, '= 5.7 Hz, 2H, CH20), 5.66-5.73 (br.,! H, 4-H) ppm.
13C-NRM (CDC13, 75MHz
d = 20.7 (q, OOCCH3), 28.4 [q, C (CH3) 3], 53.0, 53.2,
53. 3 (3t, 2-C. 5-C) *, 60.8 (t, ^ Cft, 79.5 s, c (cfl ^, 123.4, 123.8 (23.0-4), 134.5,134.6 (2s, c-3) , 154.1 { S, mjD, 170.5 (s.caOT ^ ppn.
g) 3-Acetoxy ethyl-2,5-dihydro-pyrrole-l- (N, N-di-tert-butoxyarbonyl) sarboxamidine.
To a solution of 1.21 g (5 mmol) of the 3-acetoxymethyl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butylester. For example 3f) in 10 ml of dry dioxane were added 10 ml of 4N hydrogen chloride in dioxane, the mixture was stirred at 0 ° C for 16 h. The mixture was evaporated to dry without heating and then evacuated to high vacuum for several hours. The opaque residue was suspended in 20 ml of dry acetonitrile and 776 mg (6 mmol) of ethyl diisopropylamine, followed by 1.71 g (5.5 mmol) of N, N '.bis-tert-butyloxycarbonyl-1H-pyrazole-1-carboxamidine were aggregates The mixture was stirred for 2 h at room temperature and then evaporated and purified by flash chromatography (petroleum ether / ethyl acetate 3: 1 to 2.1) to obtain 1.87 g (97%) of 3-acetoxymethyl-2, 5-dihydro- pyrrole-1- (N, N'-di-tert-butoxycarbonyl) carboxamidine, as a sticky solid.
XH-NMR (CDC13, 300 MHz)
d = 1.45 (s, 18H, 2 t-Bu), 2.03 (s, 3H, Oac), 4, .38. { br. m, 4H, 2-H, 5-H), 4.61 (s, 2H, CHaOac), 5.72 (br.m, iH, 4-H), 10.22 (br.s, IH, NH) ppm.
13 C-NMR (CDC13, 75 MHz)
d = 20.4 (q, OOCCH3), 27.7, 27.9 [2q, C (CH3) 3] ^ 55.0
(br.t, C-2, C-5), 60.2 (t, CH2OAc), 79.3, 81.8 [2br. s, C (CH3) 3], 122.4 (d, C-4), 133.5 (s, C-3), 150 (br.s, UcOO), 153.9 (s, NC = N), 162 (br. , NCOO), 170.2 (s, OOCH2CH3) ppm.
h) 3- (2-Benzydryl-deneamin-2-ethoxycarbonyl-ethyl-2,5-dihydropyrrol-1- (N, '-di-tert-butoxycarbonyl) carboxamidine
To a solution of fresh hexamethyldisilazide prepared at 0 ° C formed of 710 mg (4.4 mmol) of hexamethyldisilazone in 8 ml of THF and 1.92 g (4.4 mmol) of n-butyllithium (2.29 mmol / g in hexanes) and cooled to -78 ° C a solution of 1069 g (4 mmol) of N- (diphenylethylmethylene) -glycinate in ethyl in 8 ml of THF was added. The enolate orange solution was stirred for 30 min at -78 ° C, then a solution of 1.039 g (3.7 mmol) of 3-acetoxymethyl-2,5-dihydro-pyrrole-1- (N, N'-di- tert-butoxycarbonyl) carboxamidine and 426 mg (0.4 mmol) of Pd (PPh3) 4 in 12 ml of THF were added in the form of drops. The reaction mixture was allowed to reach room temperature for 2 hours and was stirred for 12 h. Additionally. The mixture was diluted with ether and cooled by addition of saturated NaHCO 3. The organic phase was washed with saturated NaHCO 3 and brine, dried over MgSO 4 and evaporated. Purification by flash chromatography (with ethyl acetate / petroleum ether 1: 5 + 1% triethylamine) gave 1.03 g (47%) of 3- (2-benzyldrilideneamino-2-ethoxycarbonyl-ethyl) -2,2-dihydropyrrole -1- (N, N '-di-tert-butoxycarbonyl) carboxamidine as an amorphous solid compound.
^ -NMRÍCDCls) d = 1.23 (t, j = 7.1 Hz, 3H, QCH2CH3), 1.46 [br.s, 18H, C (CH3) 3], 2.68 (br.m, 2H, 3-CH2-) 3.96 (br.m, 1H, CH-N), 4.15 (q, J = 1 .1 Hz, 2H, O R2C? .3), 4.16-4.29 (br.m, 4H, 2-H, 5-H) , 5.41 (br.m, 1H, 4-H), 7.07-7.60 (m, 10 H, Ar-H) ppm.
13 C-NMR (CDCl 3 75 MHz) d = 13.9 (q, OCH 2 CH 3), 28.0 [q, C (CH 3) 3], 32.5 (t, 3-CH 3), 55.2, 56.9 (2t, C-2, C-5 ), 60.9 (t, OCH2CH3), 63.6 (d, CH-NH2), 79, 81.6 [2 br. s, C (CH3) 3], 120.7 (d, C-4), 1-27.5, 127.8, 12-8.4, 128.6, 130.2 (-ßd, Ar-CH), 134.8 (s, C-NC = N) , 162 (br. S, NCOO), 170.7 (s, N = CPh2), 171.2 Is,
OOCH2CH3) ppm.
i) 3- (2-amino-2-ethoxysarbonyl-ethyl) -2,5, -dihydropyrrole-1 - (N, '-di-tert-butoxy-arylcarbonyl) carboxamidine
To a solution of 118 mg (0.2 mmol) of 3- (2-benzyl-drilyneamino-2-ethoxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (N, N'-di-tert-butoxycarbonyl) carboxamidine in 2 ml of THF was added 1 ml of IN hydrochloric acid. The mixture was stirred at room temperature for 30 min. Water (5 ml) was added. The aqueous phase was separated and washed twice with ether. The aqueous phase was adjusted to pH = 8.5 by adding NaHC03 IN and was extracted 5 times with ether. The combined ether phases were washed with brine, dried over MgSO4 and evaporated. The residue was purified by flash chromatography (Chloroform / methanol 20: 1) to obtain 79 mg (93%) of 3- (2-amino-2-ethoxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (NN '-di-). tert-butoxycarbonyl) carboxamidine, as a colorless oil.
^ -NMRÍCDCLs, 300 MHz)
d = 1.22 (t, j = 7.1 Hz, 3H, OCH2CH3), 1.45 [s, 18H, C (CH3) 3], 2.33 (dd, 2J = 16.6 H2.3J = 8.1 Hz, IH, CHaHbCHNH2), 2, 54 (dd, 2J016.6 HZ, 3 J = 5.3 Hz, IH, CHaHbCHNH2), 3.54 (dd, 3"= £ __1-, 5 ^ 3 Hz, IH, CHaHbCHNH2) -, 4_ 13 (q, J = 7.1 Hz, 2H, ppm.
d = 13.9 (q, OCH2CH3), 27.9 [q, C (CH3) 3], 34.1 (t, -CH2), 52.7 (d, CHNH2), 55.3, 56.9 (2d, C-2, C-5). 61.1 (t, OCH2 = CH3), ca 80 [2 br. s, C (CH3) 3], 120.7 (d, C-4), 134.6 (s, C-3) _, .53.8 (s, NC = N), 174.6 (s., OOCH2CH3) ppm.
j) 3- (2-tert-butoxycarbonyl-amino-2-ethoxycarbonylethyl) -2,5-dihydropyrrole-1 - (N, N'-di-tert-butoxycarbonyl) carboxamidine
To a solution of 79 mg (0.19 mmol) of 3-82-amino-2-ethoxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (N, N'-di-tert-butoxycarbonyl) carboxamidine in 1 ml of acetonitrile dry were added 40 mg (0.3 mmol) of ethyl diisopropylamine and 65 mg of di-tert-butyl bicarbonate
(Boc20) and the mixture was stirred for 16 h at room temperature. The solvent was evaporated and the residue was purified by flash chromatography (petroleum ether / ethyl acetate 2: 1) to obtain 83 mg (76%) of 3- (2-tert-butoxycarbonyl-amino-2-ethoxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (N, N '-di-tert-butoxycarbonyl) carboxamidine, as a colorless oil.
^ -NMRÍCDCLs, 200 MHz) d = 1.22 (t, j = 7.1 Hz, 3H, OCH2CH3), 1.42, 1.47, 1.48 [3 s, 9H each, C (CH3.}. 3], 2.41-2.66 (br. m, 2, 3-CH2-), 4.17 (q, J = 7. 1 Hz, 2H, 0CH2CH3), 4. 32 (br.m, 4H, 2-H, 5-H), 5. 02 (br ., IH, CHNH) 5 .52 (br. S, 1H 4-H) ppm.
13 C-NMR (CDC13, 50 MHz)
d = 14.1 (q, OCHCH3), 28.1, 28.3, 28.5 [3q, C.CHJJJ], 31.8 (t, 3-CH2), 48.3 (d, CHNH), 52.0, 55.3 (2t, C-2, C- 5) .61.6 (t, OCH2 = CH3), 121.3 (d and C-4), 133.5 (s, C-3), 153.9 (s, N = CN), 171.8 (s, COOEt) ppm.
NCOO-, C (CH3) 3-are not visible signs due to the extension line.
) 3- 2-tert-Butoxycarbonyl-amino-2-carboxy-ethyl) -2,5-dihydropyrrole-1- (N, NT-di-tert-butoxycarbonyl) Carboxamidine.
To a solution of 267 mg (0.63 mmol) of 3- (2-tert-butoxy-carbonyl-amino-2-ethoxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (N, N'-di-tert-butoxycarbonyl) ) carboxamidine in 5 ml of THF / methanol / water 3: 1: 1 were added 50 mg (1.2 mmol) of LiOH * H20. After 30 minutes of stirring at room temperature the original material could not be detected by TLC. The mixture was made acidic by the addition of IN HCl, diluted with water and extracted 3 times with ether. The combined organic extracts were washed with brine, dried over MgSO 4 and evaporated. The residue was purified by flash chromatography to give 98 mg
(31%) of 3- (2-tert-Butoxycarbonyl-amino-2-carboxy-ethyl) -2,5-dihydropyrrole-1- (N, N'-di-tert-butoxycarbonyl) carboxamidine (Boc-Ada (B0C2 ) -OH) as a colorless amorphous solid.
1 H-NMR (CDCL3, 300 MHz)
d = 1.39, 1.44 [2s, 9H, 18H, C (CH3) 3], 2.49-2.67 br. m, 2-H, 3-CH2) 4.33 (br., 4H, 2-H, 5-H), 5.30 (br.d, 1H, CHNH) 5.56 (br.s, 1H, 4-H) ppm.
6 = 27.7, 28.9, 28.0 [3q, C (CH3);.], 31.3 (t, 3-CH :), 52.0 (d, CHNH), 55.3, 56.9 (2t, C-2, C-5), 80.0, 80.9 [2s, (C_CH3), 121.1 (d, C-4), 133.6 (s, C-3), 153.2 (s, N = CN), 155 2 (br. S, NCOO), 176.5 (s) , COOH) ppm.
Example 2
(±) -3- (2-Fluorenylmethoxysarbonyl-amino-2-hydroxysarbonyl-1-ethyl) -2,5-dihydropyrrol-1- (N, N "-di-tert-butoxycarbonyl) carboxamidine
[Fmoc-Ada (Boc) 2OH]
a) tert-butyl ester of (±) -3- (2) acid
Benchidriliden -2-tert-butoxycarbonyl-ethyl) -2,5-dihydropyrrole-l-carboxylic acid.
To a solution of lithium hexamethyldisilazide
[fresh, prepared at 0 ° C from 1. 53 g (9.5 mmol) of hexamethyldisilazone and 4.09 g (9.5 mmol) of n-BuLi, (2.32 mmol / g in hexanes)] in 20 ml of THF was added a solution at -78 ° C of 2.79 g. (9.5 mmol) of tert-butyl-N- (diphenylmethylene) -glycinate in 20 ml of THF. The orange enolate solution was stirred for 30 minutes at -78 ° C, then a solution of 2.70 g (8.6 mmol) of 3-acetoxymethyl-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester and 243 mg 80.21 mmol) of Pd (PPh3) 4 in 20 ml of THF was added in the form of drops. The reaction mixture was allowed to warm to room temperature again and was stirred for an additional 12 h. The mixture was diluted with ether and cooled by the addition of saturated NH 4 Cl. The organic layer was washed with saturated NH 4 Cl and brine, dried with MgSO 4. and evaporated. Purification by flash chromatography (ethyl acetate / petroleum ether 1: 10 + 0.5% triethylamine) gave 3.70 g (90%) of (+) - 3- (2-Benzydrylidene-2-ter-tert-butyl ester) butoxycarbonyl-ethyl) -2,5-dihydropyrrole-1-carboxylic acid, as a slightly yellow oil.
XH-NMR (CDC13 300 MHz)
d = 1.41.1.42 [2s, 9H each, 2.62-2.71 (.2H,
3-CH2-), 3.80-4.10 (br.m, 4H, 2-H, 5-H, CHN), 5.41 (br.m, 1H, 4-H), 7.09-7.81 (m, 10H , Ar-H) ppm.
13 C-NMR (CDCl 3, 75 MHz;
d = 27.8, 28.3 [2q, C (CH3) 3], 33.0 (t, 3-CH, 52.7, 53.1, 54.5, 55.0 (4t, C-2, C-5) *, 64.2, 64.4 (2d , CH-NH2) *, 78.9 [s, C (CH3) 3] *, 81.07, 81.13 {2s C (CH3) 3] *, 121.4, 121.5 (2d, C-4) *, 127.5, 127.6, 128.1, 128.2, 128.3, 128.4, 128.6, 128.7, 130.1 (9d, Ar-CH) *, 135.8, 135.9, 136.1 (3s, Ar ~ C) *, 139.3, 139.3 (s, C-3) *, 153.8, 153.9 (2s, NCOO) *,
170. 1, 170.2 [2s, C (CH3) 3], 170.4 (s, N = CPh2) ppm.
HR-MS (FAB)
[M + H] C29H37 2? 4 cale: 477.2753
found: 477.2769
[M + Na] C2, HJ6N2? 4 at calc: 499.2573
found: 499.2570
b) (±) -3- (2-amino-2-tert-butoxycarbonyl-ethyl) -2,5-dihydropyrrole-l-carboxylic acid tert-butyl ester
To a solution of 1.57 g (3.3 mmmol) of 3- (2-benzydrylinidene-2-tert-butoxycarbonyl-ethyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester in 10 ml of THF and 5 ml of 5 ml of glacial acetic acid were added and the mixture was stirred overnight at room temperature.
The THF was evaporated in vacuo, the residue was diluted with water and made alkaline by cautious additions of K2C03 (or NH solution). The mixture was extracted three times with ethyl acetate and dried over MgSO4. Purification by flash chromatography (elution with CH_: Cl 2 MeOH 20/1) gave 1.03 g (100%) of tert-butyl ester of 3- (2-amino-2-tert-butoxycarbonyl-ethyl) -2,5- dihydropyrrole-1-carboxylic acid, as a colorless waxy solid.
^ - MR (CDC13, 300 MHz)
d = 1.41.1.42 [2s, 9H each, C (CH3) 3], 2.35 (dd, "= 14.6
Hz, 3_J = 7.4 Hz, IH, CHaHbCHNH), 2.49 (dd, 2J = 14.6 Hz, 3"= 5.8 Hz, IH, CHaHbCH Hz), 3.44 (dd, 3J = 7.4, 5.8, 5.3 Hz, IH, CHaHbCHNH2) , 4.04 (, 4H, 2-H, 5-H) ppm.
13 C-NMR (CDCI3, 75 MHz]
d = 27.8, 28.3 [2q, C (CH _.], 34.46.34.52 (t, 3-CH) *, 52.7.53.0, 54.6, (4d, C-2, C-5) * 53.2 (d, CHNH2 ), 79.0, 79.1,
L.lí 1.23 [4s, C (CH3) J] *, 121.6, 122.0 (2d, C-4;
135. 4, 135.6 (2s, C-3) *, 153.9 (s, NCOO), 174.2 (s, COOtBu) ppm.
HR-MS (FAB) [M + H] C? 6H29N2? 4 cale: 313 .2127
found: 313.2095
c) (±) -3- [2- (9-Fluorenylmethoxycarbonyl-amino) -2-tert-butoxycarbonyl-ethyl] -2,5-dihydropyrrole-l-carboxylic acid tert-butyl ester
To an ice-cooled solution of 1.03 g (3.3 mmol 9) of 3- (2-amino-2-tert-butoxycarbonyl-ethyl) -2,5-dihydropyrrole-carboxylic acid ester and 0.46 g (4.3 mmol) of Diisopropyl ethylamine in 15 ml of THF, 0.98 g (3.8 mmol) of 9-fluoromethyl chloroformate was added in one portion, the mixture was stirred at room temperature overnight, the mixture was diluted with ether, poured over water ice The aqueous layer was extracted three times with ether, the combined organic phases were dried (MgSO) and evaporated, purification by flash chromatography (ethyl acetate / petroleum ether 1: 3) gave 1.70 g (97)% of the ter- 3- [2- (9-Fluorenyl-ethoxycarbonyl-amino) -2-tert-butoxycarbonyl-ethyl] -2,5-dihydropyrrole-carboxylic acid butyl ester, as a colorless amorphous solid.
^ - MR (CDC13, 300 MHz) d = 1.45, [s, 9H, C (0.3) 3] / 2.48-2.70 (br.m, 2H,
CH¿.CHNH2). 4.05 (br.m, 4H, 2-H, 5-H), 4.20 (t, 1H, CHCH20),
4.41 (br.m, 3H, CHNH, CHCH2O), 5.36 (br.m, 1H, NH), 5.49
(br-, 1H, 4-H), 7.27-7.40 (m, 4H, Ar-H), 7.56-7.61 (m, 2H,
Ar-H). 7.73-7.76 (, 2H, Ar-H) ppm.
d = 27.7, 28.3 [2q, 0 (0.3)], 31.9.32.2 (2t, 3-CH2) *, 46.9 (d, CHCH20), 52.6 (d, CHNH2), 52.7, 53.0, 54.6 (lbr.d, 2d, C-2, C-5) *, 66.7 (t, CHCH20), 79.1, 79.2, 82.46, 82.51 [4s, C (CH3) 3] *, 119.8 (d, Ar-CH), 122.4, 122.8 ( 2d, C-4) *, 124.8, 127.3, 127.5 (3d, Ar-CH), 134.3 (br. S; C-3), 141.1, 143.6 (2s, Ar-C), 153.9, 155.4 (2s, NCOO ), 170.5 (s, COOtBu) ppm.
HR-MS (FAB)
[M] C3_H38N2? 6 cale: 535.2808
found: 535.2789
[M] C. H.jgN.O.Na calc: 557.2628 found: 557.2643
d) hydrochloride? (±) -3- (2, 5-dihydro-lH-pyrrol-3-yl) -2-fluorenimethoxycarbonylamino-propionic acid
to a solution of 588 mg (1.1 mmol) of tert-butyl é-st-er of 3- [2- (9-fluorenimethyl-methoxycarbonyl-amino) -2-tert-butoxycarbonyl-ethyl] -2,5-dihydropyrrole-1 Carboxylic acid and 376 mg (4mmol) of ethylendithiol in 5 ml of dioxane were added with 5 ml of 4N HCl in dioxane and the mixture was stirred at room temperature overnight. After 30 min a colorless solid began to precipitate. 20 ml of ether were added, the solid was filtered washed thoroughly with ether and dried in vacuo to give 433 mg (95%) of (±) -3- (2,5) dihydro-lH-pyrrole-3 hydrochloride. -yl) -2-fluorenylmethoxycarmonylamino-propionic, as a lightly colored powder.
H-NMR (CD30D, 300 MHz)
d = 2.56-2.80 (m, 2H, CH.-CHNH ^), 3.99 (br.m, 4H, 2-H, 5-H), 4.21 (t, 1H, CHCH.O), 4.31-4". 42 (m, 3H, CHNH, CHCH? O), 5.36 (br., 1H, NH), 5.62 (br.s,! H. 4-H), 7.28-7.41 (m, 4H, Ar-H), 763-768 (m, 2H, Ar-H), 7.77-7.08 (m, 3H, Ar-H) ppm.
13 C-NMR (CD3OD, 75 MHz)
d = 31.5, (t, CH;; CHNH;.), 48.3 (d, CHCHO), 53.3.53.5, 54.1 (3d, 2d, C-2, C-5, CH2CHNH), 67.9 (t, CHCH20), 120.9 (d,
Ar-CH), 122.0 (d, C-4), 126.2, 128.1, 128.8 (3d, Ar-CH),
136. 6 (s, C-39, 142.6, 145.2 (2s, Ar-C), 158.5 (s, NCOOO),
17-4.4 (s, COOH) ppm.
e) (±) -3- (2-f-uorenylmethoxycarbonyl-arnino-2-hydroxycarbonyl-1-ethyl) -2,5-dihydropyrrol-1- (N, N'-di-tert-butoxycarbonyl) carboxamidine
A suspension of 400 mg (0.96 mmol) of acid hydrochloride (± 9-3- (2,5-dihydro-lH-pyrrol-3-yl) -2-fluorenylmethoxycarbonylamino-propionic acid in 5 ml of acetonitrile were added to it. 258 mg (2 mmol) of ethyl diisopropylamine were added, followed by 298 mg (0.96 mmol) of N, N'-bis-tert-butyloxycarbonyl-1H-pyrazole-1-carboxamidine The heterogeneous mixture was stirred at room temperature by a The mixture was acidified with acetic acid, the combined organic phases were washed with brine, dried and evaporated to dryness, flash chromatography (petroleum ether / ethyl acetate 1: 1 + 1% strength). acetic acid) gave 123 mg (21%) of (±) -3- (2-fluorenylmethoxycarbonyl-amino-2-hydroxycarbonyl-ethyl) -2,5-dihydropyrrole-1- (N, N'-di-tert-butoxycarbonyl) ) carboxamidine, as a slightly yellow amorphous solid.
^ -NMR (CD3OD, 300 MHz)
d = 1.45, [s, 18H, C (CH3) 3], 2.57-2.79 (br.m, 2H, CH2CHNH2), 4.05 (br.m, 4H, 2-H, 5-H), 4.20 (t, 1H, CHCH20), 4 41 (br.m, 3H, CHNH, CHCH20), 5.36 (br.m, 1H, NH). 5.49 (br.m, 1H, 4-H), 7.24-7.37 (, 4H, Ar-H), 7.54-7.57 (, 2H, Ar-H). 7.70-7.73 (m, 2H, Ar-H) ppm.
13C-NMR (CD3OD, 75 MHz)
d = 27.7, 27.9 [2q, C (CH3) 3], 31.3, (t, CHvCHNH), 46.9 (d, CHCH20), 52.6 (d, CH2CHNH), 55.5, 57.0, (2d, C-2, C- 5), 66.8 (t, CHCH20), 81.1 [br. s, C (CH3) 3], 119.7 (d, Ar-CH), 121.2 (d, C-4), 124.9, 126.9, 127.5 (3d, Ar-CH), 133.6 8s, C-3), 141.1, 143.6 (2s, Ar-C) 153.0, 155.8 2s, NCOO), 176.5 (s, COOtBu) ppm.
HR-MS (FAB)
[M] C33H4XN4? 8 cale: 621.2924
found: 621.2881
Example 3
Ada-SAW
The title compound was synthesized by a solid-phase methodology on a multiple SyRo II peptide synthesizer (Multisyn Tech, Bochum) on a 0.03 mmol scale using Fmoc-L-Trp-trityl-polystyrene (1%) divinylbenzene resin (Fmoc -1-trp-TCP; loading: 0.57 mmol / g; PepChem, Tübiguen) as starting material. The D-amino groups of the proteinogenic amino acids Ala and Ser were protected by 9-fluorenylmethoxycarbonyl (Fmoc), the side chain alkoxide group of Ser by tert-butyl. Ada non-proteinogenic amino acids were used as Boc-Ada (Boc2) -OH (from Example 1). The protected Fmoc amino acids were paired in an excess of 6 folds per 30 min in DMF. Tbtu (1 EQ) and NMM (1 EQ) were used as activating agents. The unfolding of the Fmoc group was carried out in Piperidine / dimethylformamide (1: 1 v / v) for 2 x 10 min. the Boc-Ada (Boc2) -OH kit was manually executed in DMF in lh by using = .048 mmol of the protected amino acid (in an excess of 1.6 folds) and equimolar amounts of TBTU and NMM for activation. The peptide was split from the resin with 750 ul of acetic acid / trifluoromethanol / dichloromethane (30:10:70) in two h. After washing five times with 150 ul of the same solvent mixture the filtrate was combined, diluted, with 10 ml of heptane and concentrated. This procedure was repeated twice to remove the acetic acid completely. The oily residue was dissolved in 5 ml of 4N hydrogen chloride in dioxane. To this solution were added 270 ul of ethanedithiol and the mixture was stirred 3 h at room temperature. Then the solvent was removed and the residue dissolved in heptane and concentrated again several times until the ethanedithiol was almost completely removed. The crude peptide was lyophilized from tert-butanol / water (1: 1) and purified by HPLC preparation to obtain 9.5 mg of Ada-SAW as a colorless lyophysylate (purity by HPLC> 90%)
ESI-MS m / z 543.3 M +
Example 4
Ada-ava- The title peptide was prepared in the same manner as in Example 3 starting from 50 mg (0.03 mmol) of the Fmoc-L-Trp-TCP resin using protected Fmoc aminovaleric acid. Obtaining 6.2 mg Ada-Ava-W as a colorless lyophilisate (purity by HPLC> 90%)
ESI-MS m / z 484 .3 M +
Example 5 Ada-Aba-
The title peptide was prepared in the same manner as in the example starting from 50 mg (0.03 Mmol) of the Fmsc-L-Trp-TCP resin using protected Fmoc aminobutyric acid. Obtaining 4.8 mg Ada-Aba-W as a colorless lyophilisate (purity by HPLC> 90%).
ESI-MS m / z 470.3 Nf Example 6 T-Ada-SA
The title compound was synthesized by a solid phase methodology on a Syro II multiple peptide synthesizer (MultiSynTeach, Bochum) on a 0.03 mmol scale using Fmoc-L-Trp_Trityl-polystyrene (1%) divinylbenzene resin (Fmoc-L -Trp-TCP, loaded 0.57 mmol / g PepChe, Tubigen) as starting material. The amines groups of the proteinogenic amino acids Ala and Ser were protected by 9-fluorenylmethoxycarbonyl (Fmoc), the side chain hydroxy groups of Ser by tert-butyl. Ada non-proteinogenic amino acids were used as Fmoc-ada (Boc2) -OH (from Example 2). The protected amino acids of the Fmoc were coupled in an excess of 6 for 30 minutes in DMF. TBTU (1 Eq) and NMM (1 eq) were used as activating reagents. The unfolding of the Fmoc group was carried out in piperidine / dimethylformamide (1: 1 v / v) for 2x10 min. the coupling of Boc-Ada (Boc2) -OH and Thr was performed manually in DMF in 1 h by using 0.048 mmol of the protected amino acid Boc-Ada- (Boc2) -OH (in excess of 1.65 times) an excess 6 times in the case of Thr. Equimolar amounts of TBTU and NMM were used for activation. The peptide was separated from the resin with 750 ul of acetic acid / trifluoromethanol / dichloromethane (30:10:70) in 2 h. After washing five times with 150 ul of the same mixture of solvents the filtrates were combined, diluted with 10 ml of heptane and concentrates. This procedure was repeated twice to remove the acetic acid completely. The oily residue was dissolved in 5 ml of 4N hydrogen chloride in dioxane. To this solution were added 270 ul of ethanedithiol and the mixture was stirred for 3 h at room temperature. Then the solvent was removed and the residue dissolved in heptane and concentrated again several times until the ethanedithiol was almost completely removed. The crude peptide was lyophilized from ter. -butanol / water (1: 1) and purified by preparative HPLC to obtain 2.6 mg of T-Ada-SAW as a colorless lifilizate (purity by HPLC> 90%)
ESI-MS: m / z 644.3 M *
Example 7
T-Ada-Ava-W
The title peptide was prepared in the same manner as Example 6 starting from 50 mg (0.03 mmol) of Fmoc-L-Trp-TCP resin using aminovaleric acid protected with Fmoc. Obtaining: 2.7 mg of T-Ada-Ava-W as a colorless lyophilisate (purity by HPLC> 95%) ESI-MS: m / z585.3 M +
Example 8
T-Ada-Aba-W
The title peptide was prepared in the same manner as Example 6 starting from 50 mg (0.03 mmol) of the Fmoc-L-Trp-TCP resin using aminobutyric acid protected by Fmoc. Obtaining: 2.7 mg of T-Ada-Aba-W as a colorless lyophilisate (purity by HPLC> 95%).
ESI-MS: m / z 585.3 M *
Example 9
Biological activity
The compounds of general formula (I) were tested in an in vitro DNA synthesis assay. The cells -used were primary cultures of osteoblasts from fetuses of bald rats. The experiments were performed analogously as published in Pfeilschifter et al., Endocrinology 126, 703 (1990).
It is noted that in relation to this date, the best method known to the applicant, to carry out the aforementioned invention is that which is clear from the present description of the invention.
Having described the invention as an antecedent, the content of the following is claimed as property:
Claims (9)
1. - Compounds of general formula (i; characterized in that Ri, R2, R3 and X can be the same or different, and characterized in that Ri, R2, represent a hydrogen radical, an amino acid, peptide, alkyl or aryl. R3 represents hydroxide, lower alkoxide, or an NR31R3_ where R3i, and R32 independently represent hydrogen or an amino acid, peptide, alkyl or aryl radicals X represents an amino acid or a peptide; R4 represents hydrogen, hydroxide, amino or alkyl C? -C4; m represents a number between 0 and 5; R5 represents a mono- or bicyclic, unsaturated or saturated, optionally substituted moiety which may contain one or more heteroatoms, a C 1 -C 4 alkyl group which may have intermittent substitutions or heteroatoms, its tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs .
2. Compounds of general formula I of claim 1, characterized in that Ri and R2 are hydrogen.
3. Compounds of general formula I of any of claims 1-2 characterized in that R 3 represents hydroxide or amino.
4. Compounds of general formula I of any of claims 1-4, characterized in that R 4 represents hydroxide or methyl.
5. The compounds of general formula I of any of claims 1-4, characterized in that m represents a number 1,2 or 3.
6. The compounds of the general formula I of any of claims 1-4, characterized in that (CHR4) _QR5 represents a radical linked to an o? ^ Of a proteinogenic or non-proteinogenic amino acid.
7. The compounds of general formula (IV) characterized in that Rd represents a protecting group, for example, the benzoyl group, an alkoxycarbonyl group or the benzyloxycarbonyl group. R9 represents .Fmoc or another protecting group useful for orthogonal synthesis, Y represents COOH or C00-C? -C4-alkyl.
8. A pharmaceutical product that includes at least one of the compounds of formula I of any of claims 1 to 6.
9. The use of a compound of general formula I of any of claims 1 to 6 in a method of preparing drugs for the treatment of bone disorders. P eptides that contain an arginine mimetic for the treatment of bone metabolic disorders, their production and medicines that contain these compounds. Summary of the invention. The present invention is directed to compounds of general formula (I), wherein R1, R1, R1 and X may be the same or different, and wherein Ri, R_ represent a hydrogen, an amino acid, peptide or an alkyl or aryl radical; R3 represents hydroxide, or lower alkoxide or aryl radical, or a radical -NR3? R32, where. R 31; R 32 independently represent hydrogens, an amino acid, peptidyl, alkyl or aryl radical; X represents an amino acid or a peptide; R4 represents hydrogen, hydroxide, amine or d-Cs, alkyl; m represents a number between '0 and 5; R5 represents an optional saturated or unsaturated mono- or bicyclic substitute portion which may contain one or more heteroatoms, a Ci-Cn alkyl group which may have intermittent substitutions or heteroatoms, its tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs as well as its production and its use as medicines.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97115402 | 1997-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00002245A true MXPA00002245A (en) | 2001-03-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2766148C1 (en) | Improved apelin receptor agonists (apj) and their use | |
US6429288B1 (en) | Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds | |
CA2155448A1 (en) | Inhibitors of farnesyl protein transferase | |
IE62334B1 (en) | Phosphinic acid derivatives | |
KR19980703151A (en) | Lactam-containing hydroxamic acid derivatives, their preparation and their use as inhibitors of matrix metalloproteases | |
US6235717B1 (en) | Pharmaceutical compounds | |
WO1996032943A1 (en) | 3-substituted piperidines promote release of growth hormone | |
HU181087B (en) | Process for producing mercapto-acyl-dipeptides | |
JP4047365B2 (en) | Cycloalkanecarboxamide derivative and method for producing the same | |
US5494897A (en) | Endothelin antagonistic peptide | |
SK14699A3 (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
EP0187037A2 (en) | Piperidine derivatives, their production and use | |
KR870000810B1 (en) | Preparation of peptide-subsituted heterocyclic compounds | |
JP4427326B2 (en) | Antibacterial macro ring | |
EP0036713B1 (en) | Angiotensin converting enzyme inhibitors | |
MXPA00002245A (en) | Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds | |
EP0207680B1 (en) | Chemical compounds | |
JP2868560B2 (en) | Purine derivatives with pharmaceutical action | |
HU206369B (en) | Process for producing di- and tripeptides stimulating the immune system | |
US4714757A (en) | Aminopeptidase inhibitors | |
HU188177B (en) | Process for producing new proline derivatives | |
CA2013475A1 (en) | Amino acid derivatives | |
JP4008019B1 (en) | Cycloalkylcarbonyl amino acid ester derivative and method for producing the same | |
JPH0925293A (en) | Histidyl hydroxamic acid derivative | |
JPH0667902B2 (en) | Process for producing 3-thiopropionic acid derivative |